CA3162727A1 - Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine - Google Patents
Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine Download PDFInfo
- Publication number
- CA3162727A1 CA3162727A1 CA3162727A CA3162727A CA3162727A1 CA 3162727 A1 CA3162727 A1 CA 3162727A1 CA 3162727 A CA3162727 A CA 3162727A CA 3162727 A CA3162727 A CA 3162727A CA 3162727 A1 CA3162727 A1 CA 3162727A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- cov
- sars
- glycoprotein
- trimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 title claims abstract description 101
- 229960005486 vaccine Drugs 0.000 title claims description 44
- 108010030416 proteoliposomes Proteins 0.000 title claims description 13
- 108010001267 Protein Subunits Proteins 0.000 claims abstract description 133
- 102000002067 Protein Subunits Human genes 0.000 claims abstract description 133
- 239000013638 trimer Substances 0.000 claims abstract description 100
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 11
- 230000007017 scission Effects 0.000 claims abstract description 11
- 102000004961 Furin Human genes 0.000 claims abstract description 9
- 108090001126 Furin Proteins 0.000 claims abstract description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 74
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 210000004899 c-terminal region Anatomy 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 208000025721 COVID-19 Diseases 0.000 claims description 15
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 12
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 239000003725 proteoliposome Substances 0.000 claims description 11
- 238000005829 trimerization reaction Methods 0.000 claims description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000001268 conjugating effect Effects 0.000 claims description 5
- 102100034013 Gamma-glutamyl phosphate reductase Human genes 0.000 claims description 4
- 101001133924 Homo sapiens Gamma-glutamyl phosphate reductase Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 42
- 230000003053 immunization Effects 0.000 description 39
- 238000002649 immunization Methods 0.000 description 39
- 238000006386 neutralization reaction Methods 0.000 description 32
- 241001678559 COVID-19 virus Species 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 101710167605 Spike glycoprotein Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 241001112090 Pseudovirus Species 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 238000004132 cross linking Methods 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 241000282553 Macaca Species 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 11
- 241000282567 Macaca fascicularis Species 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108091027544 Subgenomic mRNA Proteins 0.000 description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 8
- 238000001493 electron microscopy Methods 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 6
- 101710139375 Corneodesmosin Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- -1 cobalt cation Chemical class 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 101710189104 Fibritin Proteins 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229940025291 Sinovac-CoronaVac COVID-19 vaccine Drugs 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002409 epiglottis Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000005337 ground glass Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 238000002439 negative-stain electron microscopy Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- STGOXLCCKKFIGD-UHFFFAOYSA-N 1-hydroxy-2,5-dioxopyrrolidine-3,3-disulfonic acid Chemical compound ON1C(=O)CC(S(O)(=O)=O)(S(O)(=O)=O)C1=O STGOXLCCKKFIGD-UHFFFAOYSA-N 0.000 description 1
- LMRJHNFECNKDKH-UHFFFAOYSA-N 4-(trifluoromethyl)nicotinic acid Chemical compound OC(=O)C1=CN=CC=C1C(F)(F)F LMRJHNFECNKDKH-UHFFFAOYSA-N 0.000 description 1
- SYFQYGMJENQVQT-UHFFFAOYSA-N 6-amino-2-[bis(carboxymethyl)amino]hexanoic acid Chemical compound NCCCCC(C(O)=O)N(CC(O)=O)CC(O)=O SYFQYGMJENQVQT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 102100023109 Bile acyl-CoA synthetase Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108700022167 ChAdOx1 nCoV-19 Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 229940025109 Oxford–AstraZeneca COVID-19 vaccine Drugs 0.000 description 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101150016678 RdRp gene Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101100316897 Severe acute respiratory syndrome coronavirus 2 E gene Proteins 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220590625 Spindlin-1_P26S_mutation Human genes 0.000 description 1
- 102220590630 Spindlin-1_T20N_mutation Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- GDSCFOSHSOWNDL-UHFFFAOYSA-N Zolasepam Chemical compound N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F GDSCFOSHSOWNDL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZYHMJXZULPZUED-UHFFFAOYSA-N propargite Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1C(OS(=O)OCC#C)CCCC1 ZYHMJXZULPZUED-UHFFFAOYSA-N 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 102220033185 rs62646881 Human genes 0.000 description 1
- QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004523 tiletamine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 229960001366 zolazepam Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
A recombinant SARS-CoV-2 S glycoprotein ectodomain trimer is disclosed, comprising three recombinant protomers each containing at least the SARS-CoV-2 S glycoprotein ectodomain, and wherein: in each protomer, the furin cleavage site is inactivated/disrupted; Arg408 of one of said protomers is covalently linked to Lys378 of another one of said protomers; and Lys947 of one of said protomers is covalently linked to Arg1019 and/or to Lys776 of another one of said protomers.
Description
ECTODOMAIN AND THEIR USE AS A VACCINE
TECHNICAL FIELD
The invention relates to the field of preventing and/or treating a coronavirus infection, in particular a SARS-CoV-2 infection.
More particularly, the invention relates to a recombinant SARS-CoV-2 S
glycoprotein ectodomain trimer stabilized in the native conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.
BACKGROUND OF THE INVENTION
The severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, a beta-coronavirus, is the etiological agent of coronavirus disease 2019 (COVID-19), which quickly developed into a worldwide pandemic causing more than 5 million deaths as of November 2021 and highlighting the urgent need for effective infection control and prevention.
An important correlate of protection of antiviral vaccines is the generation of neutralizing antibodies. The main SARS-CoV-2 target for inducing neutralizing antibodies is the spike (S) glycoprotein, which plays an essential role in virus attachment, fusion and entry into host cells, in particular due to its surface location. The S glycoprotein is composed of the S1 subunit that harbors the receptor-binding domain (RBD) and the S2 membrane fusion subunit that anchors the S trimer in the virus membrane.
RBD binding to the cellular receptor Angiotensin-converting enzyme 2 (ACE2) leads to virus attachment and subsequent S2-mediated fusion with endosomal membranes establishes infection. The S glycoprotein is synthesized as a trimeric precursor polyprotein that is proteolytically cleaved by furin and furin-like proteases in the Golgi generating the non-covalently linked S1-S2 heterotrimer.
The structure of the S glycoprotein reveals a compact heterotrimer composed of 51 (NTD, RBD, RBM and two subdomains), S2 (the transmembrane region) and a cytoplasmic domain. The conformation of RBD is in a dynamic equilibrium between either all RBDs in a closed, receptor-inaccessible conformation or one Date Recue/Date Received 2022-06-15
TECHNICAL FIELD
The invention relates to the field of preventing and/or treating a coronavirus infection, in particular a SARS-CoV-2 infection.
More particularly, the invention relates to a recombinant SARS-CoV-2 S
glycoprotein ectodomain trimer stabilized in the native conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.
BACKGROUND OF THE INVENTION
The severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, a beta-coronavirus, is the etiological agent of coronavirus disease 2019 (COVID-19), which quickly developed into a worldwide pandemic causing more than 5 million deaths as of November 2021 and highlighting the urgent need for effective infection control and prevention.
An important correlate of protection of antiviral vaccines is the generation of neutralizing antibodies. The main SARS-CoV-2 target for inducing neutralizing antibodies is the spike (S) glycoprotein, which plays an essential role in virus attachment, fusion and entry into host cells, in particular due to its surface location. The S glycoprotein is composed of the S1 subunit that harbors the receptor-binding domain (RBD) and the S2 membrane fusion subunit that anchors the S trimer in the virus membrane.
RBD binding to the cellular receptor Angiotensin-converting enzyme 2 (ACE2) leads to virus attachment and subsequent S2-mediated fusion with endosomal membranes establishes infection. The S glycoprotein is synthesized as a trimeric precursor polyprotein that is proteolytically cleaved by furin and furin-like proteases in the Golgi generating the non-covalently linked S1-S2 heterotrimer.
The structure of the S glycoprotein reveals a compact heterotrimer composed of 51 (NTD, RBD, RBM and two subdomains), S2 (the transmembrane region) and a cytoplasmic domain. The conformation of RBD is in a dynamic equilibrium between either all RBDs in a closed, receptor-inaccessible conformation or one Date Recue/Date Received 2022-06-15
2 or two RBDs in the "up", receptor-accessible, conformation. Only S RBD in the 'up' position allows receptor binding, which triggers the S2 post fusion conformation in proteolytically cleaved S glycoprotein (Yan et al. (2020).
Science 367, 1444-1448 ; Lan et al. (2020). Nature 58/, 215-220).
Antibodies targeting the S glycoprotein were identified upon SARS-CoV-2 seroconversion, which mostly target RBD that is immunodominant (Piccoli et al.
(2020). Cell /83, 1024-1042). This led to the isolation of many neutralizing antibodies, which confirmed antibody-based vaccination strategies. Many of these antibodies have been shown to provide in vivo protection against SARS-Cov-2 challenge in small animals and nonhuman primates or are in clinical development and use (Weinreich et al. (2021). N Engl J Med 384,238-251).
The magnitude of antibody responses to S glycoprotein during natural infection varies greatly and correlates with disease severity and duration. Basal responses are generally maintained for months or decline within weeks after infection, notably in asymptomatic individuals. Thus, any vaccine-based approach aims to induce long-lasting immunity.
A number of animal models have been developed to study SARS CoV-2 infection including the macaque model, which demonstrated induction of innate, cellular and humoral responses upon infection conferring partial protection against reinfection (Deng et al. (2020). Science 369, 818-823). Consequently, many early vaccine candidates provided protection in the macaque model including the currently licensed vaccines based on S-specific mRNA delivery (BNT162b2, Pfizer/BioNTech; mRNA-1273, Modema), adenovirus vectors (ChAdOx1 nCoV-19, Oxford/AstraZeneca; Ad26.COV2.S, Johnson & Johnson) and inactivated SARS-CoV-2 (PiCoVacc/CoronaVac, Sinovac). Employing the classical subunit approach, S glycoprotein subunit vaccine candidates have generated different levels of neutralizing antibody responses in preclinical testing (Liang et al.
(2021). Nat Commun 12, 1346).
SUMMARY OF THE INVENTION
The inventors have now discovered that a recombinant SARS-CoV-2 S
glycoprotein ectodomain trimer comprising specific modifications, when integrated in synthetic virus-like particles employing liposomes, efficiently protects animals to which it is administered from infections by at least wild-type Date Recue/Date Received 2022-06-15
Science 367, 1444-1448 ; Lan et al. (2020). Nature 58/, 215-220).
Antibodies targeting the S glycoprotein were identified upon SARS-CoV-2 seroconversion, which mostly target RBD that is immunodominant (Piccoli et al.
(2020). Cell /83, 1024-1042). This led to the isolation of many neutralizing antibodies, which confirmed antibody-based vaccination strategies. Many of these antibodies have been shown to provide in vivo protection against SARS-Cov-2 challenge in small animals and nonhuman primates or are in clinical development and use (Weinreich et al. (2021). N Engl J Med 384,238-251).
The magnitude of antibody responses to S glycoprotein during natural infection varies greatly and correlates with disease severity and duration. Basal responses are generally maintained for months or decline within weeks after infection, notably in asymptomatic individuals. Thus, any vaccine-based approach aims to induce long-lasting immunity.
A number of animal models have been developed to study SARS CoV-2 infection including the macaque model, which demonstrated induction of innate, cellular and humoral responses upon infection conferring partial protection against reinfection (Deng et al. (2020). Science 369, 818-823). Consequently, many early vaccine candidates provided protection in the macaque model including the currently licensed vaccines based on S-specific mRNA delivery (BNT162b2, Pfizer/BioNTech; mRNA-1273, Modema), adenovirus vectors (ChAdOx1 nCoV-19, Oxford/AstraZeneca; Ad26.COV2.S, Johnson & Johnson) and inactivated SARS-CoV-2 (PiCoVacc/CoronaVac, Sinovac). Employing the classical subunit approach, S glycoprotein subunit vaccine candidates have generated different levels of neutralizing antibody responses in preclinical testing (Liang et al.
(2021). Nat Commun 12, 1346).
SUMMARY OF THE INVENTION
The inventors have now discovered that a recombinant SARS-CoV-2 S
glycoprotein ectodomain trimer comprising specific modifications, when integrated in synthetic virus-like particles employing liposomes, efficiently protects animals to which it is administered from infections by at least wild-type Date Recue/Date Received 2022-06-15
3 SARS-CoV-2 and Alpha pseudovirus variants, and neutralizes Beta and Gamma pseudovirus variants at reduced potency, by providing sterilizing immunity, more particularly by eliciting mucosal immune responses. Moreover, RBD-specific antibodies are predominant after a first and second immunization, but, after a third immunization median S-specific ED50s are 3 times higher than RBD-specific ED50s, suggesting that more than two immunizations allow to expand the reactive B cell repertoire that target non-RBD S epitopes, which proves particularly advantageous in the field of development of vaccines against native SARS-CoV-2 and variants thereof.
More particularly, an object of the invention is a recombinant SARS-CoV-2 S
glycoprotein ectodomain trimer comprising three recombinant protomers each containing at least the SARS-CoV-2 S glycoprotein ectodomain, wherein, at least:
- in each protomer, the furin cleavage site, situated at positions 682 to in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ
ID No: 1), is inactivated/disrupted;
- the amino acid residue located at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue located at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers; and - the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue located at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers and/or the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue located at position 776 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID
No: 1) of another one of said protomers.
The trimer having these characteristics is advantageously stabilized in the native conformation.
Date Recue/Date Received 2022-06-15
More particularly, an object of the invention is a recombinant SARS-CoV-2 S
glycoprotein ectodomain trimer comprising three recombinant protomers each containing at least the SARS-CoV-2 S glycoprotein ectodomain, wherein, at least:
- in each protomer, the furin cleavage site, situated at positions 682 to in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ
ID No: 1), is inactivated/disrupted;
- the amino acid residue located at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue located at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers; and - the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue located at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers and/or the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue located at position 776 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID
No: 1) of another one of said protomers.
The trimer having these characteristics is advantageously stabilized in the native conformation.
Date Recue/Date Received 2022-06-15
4 In particular embodiments of the invention, each protomer of said trimer recombinant SARS-CoV-2 S glycoprotein ectodomain is such that:
- the amino acid residues situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) are substituted by an amino acid motif of sequence GSAS (SEQ ID No: 2);
and/or - it is linked to a C-terminal trimerization domain; and/or - it comprises at least two proline substitutions at positions 986 and 987 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ
ID No: 1); and/or - it is linked to at least one tag at its C-terminal end; and/or - it comprises, in particular it consists of, the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein or a protein having at least 90 % amino acid sequence identity therewith.
In particular embodiments:
- the amino acid residue located at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue, the amino acid residue located at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, and said arginine residue of one of said protomers and said lysine residue of another one of said protomers are linked by a methylene bridge; and/or - the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, the amino acid residue located at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue, and said lysine residue of one of said protomers and said arginine residue of another one of said protomers are linked by a methylene bridge; and/or - the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, the amino acid residue located at position 776 in the amino acid Date Recue/Date Received 2022-06-15
- the amino acid residues situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) are substituted by an amino acid motif of sequence GSAS (SEQ ID No: 2);
and/or - it is linked to a C-terminal trimerization domain; and/or - it comprises at least two proline substitutions at positions 986 and 987 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ
ID No: 1); and/or - it is linked to at least one tag at its C-terminal end; and/or - it comprises, in particular it consists of, the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein or a protein having at least 90 % amino acid sequence identity therewith.
In particular embodiments:
- the amino acid residue located at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue, the amino acid residue located at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, and said arginine residue of one of said protomers and said lysine residue of another one of said protomers are linked by a methylene bridge; and/or - the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, the amino acid residue located at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue, and said lysine residue of one of said protomers and said arginine residue of another one of said protomers are linked by a methylene bridge; and/or - the amino acid residue located at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, the amino acid residue located at position 776 in the amino acid Date Recue/Date Received 2022-06-15
5 sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue and said lysine residues are linked by a methylene bridge.
In particular embodiments of the invention, the trimer is a homomeric trimer.
According to the invention, a method of producing such a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer comprises expressing nucleic acid molecule(s) encoding said protomers in a host cell to produce said trimer, purifying said trimer and treating said trimer with formaldehyde.
Another object of the invention is a proteoliposome comprising a lipid vesicle a surface of which is coated by a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention.
A method of preparing such a proteoliposome comprises incubating said trimer with said lipid vesicle.
Another object of the invention is a vaccine comprising proteoliposomes of the invention, and optionally a pharmaceutically acceptable carrier and/or an adjuvant.
The invention also relates to the use of the vaccine of the invention for treating or preventing a SARS-CoV-2 infection in a subject.
The vaccine may in particular be administered to the subject intramuscularly or intranasally.
BRIEF DESCRIPTION OF THE FIGURES
The features and advantages of the invention will emerge more clearly in the light of the following examples of implementation, provided for illustrative purposes only and in no way !imitative of the invention, with the support of figures 1 to 7.
Figure 1 shows the results of structural characterization of a trimer of the invention (FA-S) and proteoliposomes based on this trimer (FA-S-LVs). (A) Left panel, cryo-EM density of FA-S with all three RBD down. The structure was calculated from 126,719 particles imposing C3 symmetry; middle panel, molecular model of FA-S refined to a resolution of 3.4 A shown as ribbon.
Modeled N-linked glycans are shown as all atom models; right panel, two major cross-linking sites were identified that covalently link RBDs and the S2 subunits from different protomers. (B) Close-up of the cross-linking sites between RBDs (left panel); formaldehyde cross-linked amino groups of K378 and R408 of Date Recue/Date Received 2022-06-15
In particular embodiments of the invention, the trimer is a homomeric trimer.
According to the invention, a method of producing such a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer comprises expressing nucleic acid molecule(s) encoding said protomers in a host cell to produce said trimer, purifying said trimer and treating said trimer with formaldehyde.
Another object of the invention is a proteoliposome comprising a lipid vesicle a surface of which is coated by a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention.
A method of preparing such a proteoliposome comprises incubating said trimer with said lipid vesicle.
Another object of the invention is a vaccine comprising proteoliposomes of the invention, and optionally a pharmaceutically acceptable carrier and/or an adjuvant.
The invention also relates to the use of the vaccine of the invention for treating or preventing a SARS-CoV-2 infection in a subject.
The vaccine may in particular be administered to the subject intramuscularly or intranasally.
BRIEF DESCRIPTION OF THE FIGURES
The features and advantages of the invention will emerge more clearly in the light of the following examples of implementation, provided for illustrative purposes only and in no way !imitative of the invention, with the support of figures 1 to 7.
Figure 1 shows the results of structural characterization of a trimer of the invention (FA-S) and proteoliposomes based on this trimer (FA-S-LVs). (A) Left panel, cryo-EM density of FA-S with all three RBD down. The structure was calculated from 126,719 particles imposing C3 symmetry; middle panel, molecular model of FA-S refined to a resolution of 3.4 A shown as ribbon.
Modeled N-linked glycans are shown as all atom models; right panel, two major cross-linking sites were identified that covalently link RBDs and the S2 subunits from different protomers. (B) Close-up of the cross-linking sites between RBDs (left panel); formaldehyde cross-linked amino groups of K378 and R408 of Date Recue/Date Received 2022-06-15
6 neighboring protomers as indicated by the continuous density connecting side chains (right panel). (C) Close-up of the cross-linking sites between S2 (left panel); continuous density between the central helix R1019 as well as S2 K776 to S2 HR1K947 shows two alternative cross-links between protomers with equal occupancy (right panel). (D) Analyzis by negative staining electron microscopy of FA-S-LVs, revealing regular decoration of the liposomes with the S trimer.
Counting FA-S trimer on 50 FA-S-LVs (negative staining EM two-dimensional vision) indicated 231 92 trimers. It is thus estimated that approximately or at least 460 184 FA-S trimers are attached to the LVs. Scale bar, 200 nm.
Figure 2 shows the results of analysis of antibody responses induced by FA-S-LVs vaccination of cynomolgus macaques. (A) Scheme of vaccination, challenge and sampling. Syringes indicate the time points of vaccination and the virus particle indicates the time point of challenge. Symbols of identifying individual macaques are used in all figures. (B) ELISA of SARS-CoV-2 S-protein-specific IgG determined during the study at weeks 0, 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, Ab titers of individual animals are shown. (C) ELISA of SARS-CoV-2 FA-S-protein-specific IgG determined during the study at the indicated weeks. (D) ELISA of SARS-CoV-2 S RBD-specific IgG determined during the study at the indicated weeks. For panels (B), (C), and (D), differences between matched groups were compared using the Wilcoxon signed-rank test (p<0.1). (E and F) Detection of 5-specific IgG (E) and IgA (F) in nasopharyngeal fluids. Relative mean fluorescence intensity (MFI) of IgG and IgA binding to SARS-CoV-2 S measured with a Luminex-based serology assay in nasopharyngeal swabs. The background level is indicated by dotted lines. The vertical line indicates the day of challenge. For panels (E), and (F), groups were compared using the Mann-Whitney U test (*p < 0.05). Data presented in A to F are from technical duplicates.
Figure 3 shows the serum neutralization of SARS-CoV-2 pseudovirus upon FA-S-LVs vaccination. (A) The evolution of SARS-CoV-2 neutralizing Ab titers is shown for sera collected at weeks 0, 2, 4, 6, 8, 11, 12, 19. Bars indicate median titers of the four animals. Differences between matched groups were compared using the Wilcoxon signed-rank test (p<0.1). Data presented are from technical duplicates. (B) Serum from week 11 was depleted of RBD-specific Abs by affinity chromatography and neutralization activity of the complete serum of each animal Date Recue/Date Received 2022-06-15
Counting FA-S trimer on 50 FA-S-LVs (negative staining EM two-dimensional vision) indicated 231 92 trimers. It is thus estimated that approximately or at least 460 184 FA-S trimers are attached to the LVs. Scale bar, 200 nm.
Figure 2 shows the results of analysis of antibody responses induced by FA-S-LVs vaccination of cynomolgus macaques. (A) Scheme of vaccination, challenge and sampling. Syringes indicate the time points of vaccination and the virus particle indicates the time point of challenge. Symbols of identifying individual macaques are used in all figures. (B) ELISA of SARS-CoV-2 S-protein-specific IgG determined during the study at weeks 0, 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, Ab titers of individual animals are shown. (C) ELISA of SARS-CoV-2 FA-S-protein-specific IgG determined during the study at the indicated weeks. (D) ELISA of SARS-CoV-2 S RBD-specific IgG determined during the study at the indicated weeks. For panels (B), (C), and (D), differences between matched groups were compared using the Wilcoxon signed-rank test (p<0.1). (E and F) Detection of 5-specific IgG (E) and IgA (F) in nasopharyngeal fluids. Relative mean fluorescence intensity (MFI) of IgG and IgA binding to SARS-CoV-2 S measured with a Luminex-based serology assay in nasopharyngeal swabs. The background level is indicated by dotted lines. The vertical line indicates the day of challenge. For panels (E), and (F), groups were compared using the Mann-Whitney U test (*p < 0.05). Data presented in A to F are from technical duplicates.
Figure 3 shows the serum neutralization of SARS-CoV-2 pseudovirus upon FA-S-LVs vaccination. (A) The evolution of SARS-CoV-2 neutralizing Ab titers is shown for sera collected at weeks 0, 2, 4, 6, 8, 11, 12, 19. Bars indicate median titers of the four animals. Differences between matched groups were compared using the Wilcoxon signed-rank test (p<0.1). Data presented are from technical duplicates. (B) Serum from week 11 was depleted of RBD-specific Abs by affinity chromatography and neutralization activity of the complete serum of each animal Date Recue/Date Received 2022-06-15
7 was set to 100 % and compared to the RBD-depleted sera and the RBD-specific sera.
Figure 4 shows results of FA-S-LVs immunization of cynomolgus macaques against SARS-CoV-2 infection. Genomic (A) and subgenomic (sg)RNA viral loads (B) in tracheal swabs (left) and nasopharyngeal swabs (middle) of control (black) and vaccinated (grey) macaques after challenge. Viral loads in control and vaccinated macaques after challenge in BAL are shown (right). Bars indicate median viral loads. Vertical dotted lines indicate the day of challenge.
Horizontal dotted lines indicate the limit of quantification. Data presented are from technical duplicates.
Figure 5 shows the results of analysis of serum antibody titers and neutralization of vaccinated and control cynomolgus macaques after SARS CoV-2 challenge.
Antibody IgG titers were determined by ELISA at weeks 24 (challenge), 25, 26, 27 and 28 against (A) SARS-CoV-2 S, (B) SARS-CoV-2 FA-S and (C) SARS-CoV-2 S RBD. Vaccinated animals are shown with grey symbols and control animals with black symbols. (D)SARS CoV-2 pseudovirus neutralization titers at week 24 (challenge) and 1, 2 and 4 weeks post exposure (weeks 25, 26, 28).
The Bars show the median titers. For panels A to D, differences between matched groups were compared using the Wilcoxon signed-rank test (p<0.1).
Data presented in A to D are from technical duplicates.
Figure 6 illustrates the antigen-specific CD4 T-cell responses in FA-S-LV
immunized cynomolgus macaques. Frequency of (A) IFNy+, TFNa+ and IL-2+, (B) Th1 (IFN y+/-, IL-2+/-, TNFa+), (C) IL-13+ and (D) IL-17+ antigen-specific CD4+ T cells (CD154+) in the total CD4+ T cell population, respectively, for each immunized macaque (n = 4) at week (W)21 post-immunization (p.im.) (i.e. two weeks after the 4th immunization, pre-exposure) and 14 days post-exposure (dpe.). PBMCs were stimulated overnight with culture medium only ("NS", light grey symbols) or with SARS-CoV-2 S overlapping peptide pools ("S1 +S2", grey symbols). Bars indicate means. Time points in each experimental group were compared using the Wilcoxon signed rank test.
Figure 7 shows robust neutralization of SARS CoV-2 variants induced by FA-S-LVs vaccination. B.1.1.7 (Alpha, UK), B.1.351 (Beta, SA) and P.1 (Gamma, BR) pseudovirus neutralization titers were compared to the Wuhan vaccine strain.
Date Recue/Date Received 2022-06-15
Figure 4 shows results of FA-S-LVs immunization of cynomolgus macaques against SARS-CoV-2 infection. Genomic (A) and subgenomic (sg)RNA viral loads (B) in tracheal swabs (left) and nasopharyngeal swabs (middle) of control (black) and vaccinated (grey) macaques after challenge. Viral loads in control and vaccinated macaques after challenge in BAL are shown (right). Bars indicate median viral loads. Vertical dotted lines indicate the day of challenge.
Horizontal dotted lines indicate the limit of quantification. Data presented are from technical duplicates.
Figure 5 shows the results of analysis of serum antibody titers and neutralization of vaccinated and control cynomolgus macaques after SARS CoV-2 challenge.
Antibody IgG titers were determined by ELISA at weeks 24 (challenge), 25, 26, 27 and 28 against (A) SARS-CoV-2 S, (B) SARS-CoV-2 FA-S and (C) SARS-CoV-2 S RBD. Vaccinated animals are shown with grey symbols and control animals with black symbols. (D)SARS CoV-2 pseudovirus neutralization titers at week 24 (challenge) and 1, 2 and 4 weeks post exposure (weeks 25, 26, 28).
The Bars show the median titers. For panels A to D, differences between matched groups were compared using the Wilcoxon signed-rank test (p<0.1).
Data presented in A to D are from technical duplicates.
Figure 6 illustrates the antigen-specific CD4 T-cell responses in FA-S-LV
immunized cynomolgus macaques. Frequency of (A) IFNy+, TFNa+ and IL-2+, (B) Th1 (IFN y+/-, IL-2+/-, TNFa+), (C) IL-13+ and (D) IL-17+ antigen-specific CD4+ T cells (CD154+) in the total CD4+ T cell population, respectively, for each immunized macaque (n = 4) at week (W)21 post-immunization (p.im.) (i.e. two weeks after the 4th immunization, pre-exposure) and 14 days post-exposure (dpe.). PBMCs were stimulated overnight with culture medium only ("NS", light grey symbols) or with SARS-CoV-2 S overlapping peptide pools ("S1 +S2", grey symbols). Bars indicate means. Time points in each experimental group were compared using the Wilcoxon signed rank test.
Figure 7 shows robust neutralization of SARS CoV-2 variants induced by FA-S-LVs vaccination. B.1.1.7 (Alpha, UK), B.1.351 (Beta, SA) and P.1 (Gamma, BR) pseudovirus neutralization titers were compared to the Wuhan vaccine strain.
Date Recue/Date Received 2022-06-15
8 Titers were determined using total IgG purified from sera at weeks 8 (2 immunizations), 12 (3 immunizations), 24 and 28 (4 immunizations). Background neutralization by IgG isolated from naïve animals was <100 for all variants and is indicated by the dashed line. Data presented are from technical duplicates.
DETAILED DESCRIPTION
Recombinant SARS-CoV-2 S glycoprotein ectodomain trimer The recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention comprises three recombinant protomers each comprising at least the SARS-CoV-2 virus S glycoprotein ectodomain.
In particularly preferred embodiments of the invention, these three protomers are identical, the trimer of the invention then being a homomeric trimer.
In alternative embodiments of the invention, these three protomers are all different from one another, or two of them are identical and the third one is different.
The SARS-CoV-2 S glycoprotein ectodomain is herein defined, in a conventional way, as the domain of the protein that extends into the extracellular space.
More particularly, in the amino acid sequence of the S glycoprotein of the firstly identified SARS-CoV-2 virus (Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1), the ectodomain of the SARS-CoV-2 S glycoprotein corresponds to amino residues 12 to 1190. The amino acid sequence of this S
glycoprotein, herein denoted "native SARS-CoV-2 S glycoprotein" (SEQ ID
No: 1) is described in the GenBank database under accession number MN908947.3 ("S" coding sequence (nucleotides 21563 to 25384)).
By SARS-CoV-2 S glycoprotein ectodomain, it is included according to the invention the ectodomain of the native SARS-CoV-2 S glycoprotein, of amino acid sequence SEQ ID No: 3, herein denoted "native ectodomain", as well as any variant thereof retaining the capacity of the native ectodomain of inducing a neutralizing antibody response and preferably having an amino acid sequence with at least 90%, preferably at least 95%, preferably at least 98% and even more preferably at least 99%, identity with the amino acid sequence SEQ ID No: 3.
Such variants may consist of the S glycoprotein ectodomain of any variant or mutant of the firstly identified SARS-CoV-2 virus, such as the variant Alpha (also known as the variant B.1.1.7), the variant Beta (also known as the variant Date Recue/Date Received 2022-06-15
DETAILED DESCRIPTION
Recombinant SARS-CoV-2 S glycoprotein ectodomain trimer The recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention comprises three recombinant protomers each comprising at least the SARS-CoV-2 virus S glycoprotein ectodomain.
In particularly preferred embodiments of the invention, these three protomers are identical, the trimer of the invention then being a homomeric trimer.
In alternative embodiments of the invention, these three protomers are all different from one another, or two of them are identical and the third one is different.
The SARS-CoV-2 S glycoprotein ectodomain is herein defined, in a conventional way, as the domain of the protein that extends into the extracellular space.
More particularly, in the amino acid sequence of the S glycoprotein of the firstly identified SARS-CoV-2 virus (Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1), the ectodomain of the SARS-CoV-2 S glycoprotein corresponds to amino residues 12 to 1190. The amino acid sequence of this S
glycoprotein, herein denoted "native SARS-CoV-2 S glycoprotein" (SEQ ID
No: 1) is described in the GenBank database under accession number MN908947.3 ("S" coding sequence (nucleotides 21563 to 25384)).
By SARS-CoV-2 S glycoprotein ectodomain, it is included according to the invention the ectodomain of the native SARS-CoV-2 S glycoprotein, of amino acid sequence SEQ ID No: 3, herein denoted "native ectodomain", as well as any variant thereof retaining the capacity of the native ectodomain of inducing a neutralizing antibody response and preferably having an amino acid sequence with at least 90%, preferably at least 95%, preferably at least 98% and even more preferably at least 99%, identity with the amino acid sequence SEQ ID No: 3.
Such variants may consist of the S glycoprotein ectodomain of any variant or mutant of the firstly identified SARS-CoV-2 virus, such as the variant Alpha (also known as the variant B.1.1.7), the variant Beta (also known as the variant Date Recue/Date Received 2022-06-15
9 B.1.351), the variant Gamma (also known as the variant P.1), the variant Delta (also known as the variant B.1.617.2), the variant Omicron (also known as the variant B.1.1.529), etc., or they may consist of any protein having at least 90%, preferably at least 95%, preferably at least 98% and even more preferably at least 99%, amino acid identity therewith and retaining the capacity thereof of inducing a neutralizing antibody response.
Variants of the native SARS-CoV-2 S glycoprotein ectodomain may in particular have, relative to the sequence of the native ectodomain, which constitutes the reference sequence, insertions, deletions and/or substitutions, in particular N-terminal and/or C-terminal modifications, and/or non-native bonds between amino acid residues. In the case of a substitution, this is preferably carried out by an amino acid of the same family as the original amino acid, for example by substitution of a basic residue such as arginine by another basic residue such as a lysine residue, of an acid residue such as aspartate by another acid residue such as glutamate, of a polar residue such as serine by another polar residue such as threonine, of an aliphatic residue such as leucine by another aliphatic residue such as isoleucine, etc.
The percentage of identity between two amino acid sequences is herein determined in a conventional way in itself, by comparing the two optimally aligned sequences, through a comparison window. The amino acid sequence to be compared and located in the comparison window may include additions or deletions with respect to the reference sequence so as to obtain an optimal alignment between the two sequences. The percentage identity is then calculated by determining the number of positions for which an amino acid residue is identical in the two sequences compared, then dividing this number of positions by the total number of positions in the window of comparison, the number obtained being multiplied by one hundred to obtain the percentage of identity between the two sequences.
Variants of the native SARS-CoV-2 S glycoprotein ectodomain described in the prior art as having improved stability, in particular in a prefusion state, are particularly preferred in the context of the invention.
In particular embodiments, at least one, preferably two and more preferably the three, of the protomers of the invention consist of the SARS-CoV-2 S
Date Recue/Date Received 2022-06-15
Variants of the native SARS-CoV-2 S glycoprotein ectodomain may in particular have, relative to the sequence of the native ectodomain, which constitutes the reference sequence, insertions, deletions and/or substitutions, in particular N-terminal and/or C-terminal modifications, and/or non-native bonds between amino acid residues. In the case of a substitution, this is preferably carried out by an amino acid of the same family as the original amino acid, for example by substitution of a basic residue such as arginine by another basic residue such as a lysine residue, of an acid residue such as aspartate by another acid residue such as glutamate, of a polar residue such as serine by another polar residue such as threonine, of an aliphatic residue such as leucine by another aliphatic residue such as isoleucine, etc.
The percentage of identity between two amino acid sequences is herein determined in a conventional way in itself, by comparing the two optimally aligned sequences, through a comparison window. The amino acid sequence to be compared and located in the comparison window may include additions or deletions with respect to the reference sequence so as to obtain an optimal alignment between the two sequences. The percentage identity is then calculated by determining the number of positions for which an amino acid residue is identical in the two sequences compared, then dividing this number of positions by the total number of positions in the window of comparison, the number obtained being multiplied by one hundred to obtain the percentage of identity between the two sequences.
Variants of the native SARS-CoV-2 S glycoprotein ectodomain described in the prior art as having improved stability, in particular in a prefusion state, are particularly preferred in the context of the invention.
In particular embodiments, at least one, preferably two and more preferably the three, of the protomers of the invention consist of the SARS-CoV-2 S
Date Recue/Date Received 2022-06-15
10 glycoprotein ectodomain. In alternative embodiments, it/they also comprise(s) additional amino acid residues of the SARS-CoV-2 S glycoprotein, for example residues Ito 11 and/or residues 1191 to 1208 thereof.
In all this description, the amino acids positions are given in reference to the sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1). These positions may be slightly different according to the variants of the SARS-CoV-S glycoprotein considered. It is within the skills of the person skilled in the art to identify these positions for a given variant, based on the particular amino acids and on a comparison of the variant's sequence with the native sequence.
Moreover, these positions do not necessarily correspond to the positions in the actual recombinant protomers, if the latter do not comprise the first amino acids of the SARS-CoV-2 S glycoprotein situated upstream the ectodomain of this S
glycoprotein. It is within the skills of the person skilled in the art to identify the position, in the protomer, of an amino acid residue defined in the context of the invention by its position in the native SARS-CoV-2 S glycoprotein sequence.
Each protomer of the trimer of the invention may comprise, or consist of, the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein, or a protein having at least 90 %, preferably at least 95 %, preferably at least 98 %, and more preferably at least 99 %, amino acid sequence identity therewith and retaining the capacity thereof to induce a neutralizing antibody response. Such a protein may in particular comprise one or more amino acid substitutions, insertions and/or deletions with respect to the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein.
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, in each protomer, the furin cleavage site is inactivated/disrupted.
This furin cleavage site is formed of the four amino acid residues corresponding to the residues that are situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) (arg682, arg683, a1a684 and arg685 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein).
Such an inactivation of this furin cleavage site increases the cellular stability of the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer, by preventing any cleavage between the S1 and S2 domains by cellular proteases such as Date Recue/Date Received 2022-06-15
In all this description, the amino acids positions are given in reference to the sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1). These positions may be slightly different according to the variants of the SARS-CoV-S glycoprotein considered. It is within the skills of the person skilled in the art to identify these positions for a given variant, based on the particular amino acids and on a comparison of the variant's sequence with the native sequence.
Moreover, these positions do not necessarily correspond to the positions in the actual recombinant protomers, if the latter do not comprise the first amino acids of the SARS-CoV-2 S glycoprotein situated upstream the ectodomain of this S
glycoprotein. It is within the skills of the person skilled in the art to identify the position, in the protomer, of an amino acid residue defined in the context of the invention by its position in the native SARS-CoV-2 S glycoprotein sequence.
Each protomer of the trimer of the invention may comprise, or consist of, the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein, or a protein having at least 90 %, preferably at least 95 %, preferably at least 98 %, and more preferably at least 99 %, amino acid sequence identity therewith and retaining the capacity thereof to induce a neutralizing antibody response. Such a protein may in particular comprise one or more amino acid substitutions, insertions and/or deletions with respect to the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein.
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, in each protomer, the furin cleavage site is inactivated/disrupted.
This furin cleavage site is formed of the four amino acid residues corresponding to the residues that are situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) (arg682, arg683, a1a684 and arg685 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein).
Such an inactivation of this furin cleavage site increases the cellular stability of the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer, by preventing any cleavage between the S1 and S2 domains by cellular proteases such as Date Recue/Date Received 2022-06-15
11 furin.
In particular embodiments, at least one, preferably two, and more preferably each, protomer of the trimer of the invention comprises 682G, 683S, 684A
and/or 685S substitution(s).
In particular embodiments, in at least one, preferably two, and more preferably in each, protomer of the trimer of the invention, the amino acid residues corresponding to those situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) are substituted by an amino acid motif of sequence GSAS (SEQ ID No: 2).
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, the amino acid residue corresponding to the amino acid residue at position 408 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue corresponding to the amino acid residue at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID
No: 1) of another one of said protomers. This cross-linking between at least two protomers of the trimer advantageously keeps the latter in the native closed "RBD-down" conformation. These amino acids may be directly linked to each other by a covalent bond, or covalently linked by a spacer arm. As an example, these amino acids can be linked to each other by a methylene bridge.
Otherwise, this cross-linking between the one protomer and the other protomer can be a non-native disulfide bond between cysteine residues introduced by suitable substitutions in the protomers.
Preferably, at least one protomer is covalently linked to another protomer by an intermolecular linkage between the amino acid at position 408 of the one protomer and the amino acid at position 378 of the other protomer. These amino acid residues can for example be attached to one another by a methylene bridge or by a non-native disulfide bond between cysteine residues introduced by a 378C substitution in the one protomer and a 408C substitution in the other protomer.
In particular embodiments of the invention, in at least one protomer, preferably in each protomer, the amino acid residue at position 408 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine Date Recue/Date Received 2022-06-15
In particular embodiments, at least one, preferably two, and more preferably each, protomer of the trimer of the invention comprises 682G, 683S, 684A
and/or 685S substitution(s).
In particular embodiments, in at least one, preferably two, and more preferably in each, protomer of the trimer of the invention, the amino acid residues corresponding to those situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) are substituted by an amino acid motif of sequence GSAS (SEQ ID No: 2).
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, the amino acid residue corresponding to the amino acid residue at position 408 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue corresponding to the amino acid residue at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID
No: 1) of another one of said protomers. This cross-linking between at least two protomers of the trimer advantageously keeps the latter in the native closed "RBD-down" conformation. These amino acids may be directly linked to each other by a covalent bond, or covalently linked by a spacer arm. As an example, these amino acids can be linked to each other by a methylene bridge.
Otherwise, this cross-linking between the one protomer and the other protomer can be a non-native disulfide bond between cysteine residues introduced by suitable substitutions in the protomers.
Preferably, at least one protomer is covalently linked to another protomer by an intermolecular linkage between the amino acid at position 408 of the one protomer and the amino acid at position 378 of the other protomer. These amino acid residues can for example be attached to one another by a methylene bridge or by a non-native disulfide bond between cysteine residues introduced by a 378C substitution in the one protomer and a 408C substitution in the other protomer.
In particular embodiments of the invention, in at least one protomer, preferably in each protomer, the amino acid residue at position 408 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine Date Recue/Date Received 2022-06-15
12 residue (Arg 408), and in at least another protomer, preferably in each protomer, the amino acid residue at position 378 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys378), and said arginine residue of one of said protomers and said lysine residue of another one of said protomers are linked by a methylene bridge.
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, at least one protomer is covalently linked to another protomer by an intermolecular linkage between S2 subunits. More particularly, the amino acid residue corresponding to the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of the protomers is covalently linked to the amino acid residue corresponding to the amino acid residue at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of the protomers, situated in the central S2 helix. This additional cross-linking between at least two protomers of the trimer advantageously stabilizes the trimer. These amino acid residues may be directly linked to each other by a covalent bond, or covalently linked by a spacer arm. As an example, these amino acid residues can be linked to each other by a methylene bridge.
Preferably, at least one protomer is covalently linked to another protomer by an intermolecular linkage between the amino acid residue at position 947 of the one protomer and the amino acid residue at position 1019 of the other protomer, in the central S2 helix. These amino acid residues can for example be linked to each other by a methylene bridge attached to a lysine residue at position 947 of the one protomer and to an arginine residue at position 1019 of the other protomer.
In particular embodiments of the invention, in at least one protomer, preferably in each protomer, the amino acid residue at position 947 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys947), and in at least another protomer, preferably in each protomer, the amino acid residue at position 1019 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue (Arg 1019), and said lysine residue of one of said protomers and said arginine residue of another one of said protomers are linked by a methylene bridge.
Date Recue/Date Received 2022-06-15
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, at least one protomer is covalently linked to another protomer by an intermolecular linkage between S2 subunits. More particularly, the amino acid residue corresponding to the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of the protomers is covalently linked to the amino acid residue corresponding to the amino acid residue at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of the protomers, situated in the central S2 helix. This additional cross-linking between at least two protomers of the trimer advantageously stabilizes the trimer. These amino acid residues may be directly linked to each other by a covalent bond, or covalently linked by a spacer arm. As an example, these amino acid residues can be linked to each other by a methylene bridge.
Preferably, at least one protomer is covalently linked to another protomer by an intermolecular linkage between the amino acid residue at position 947 of the one protomer and the amino acid residue at position 1019 of the other protomer, in the central S2 helix. These amino acid residues can for example be linked to each other by a methylene bridge attached to a lysine residue at position 947 of the one protomer and to an arginine residue at position 1019 of the other protomer.
In particular embodiments of the invention, in at least one protomer, preferably in each protomer, the amino acid residue at position 947 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys947), and in at least another protomer, preferably in each protomer, the amino acid residue at position 1019 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue (Arg 1019), and said lysine residue of one of said protomers and said arginine residue of another one of said protomers are linked by a methylene bridge.
Date Recue/Date Received 2022-06-15
13 Alternatively, or additionally, in the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, at least one protomer is covalently linked to another protomer by a different intermolecular linkage between S2 subunits.
More particularly, the amino acid residue corresponding to the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein (SEQ ID No: 1) of one of the protomers is covalently linked to the amino acid residue corresponding to the amino acid residue at position 776 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID
No: 1) of another one of the protomers. This additional cross-linking between at least two protomers of the trimer also advantageously stabilizes the trimer.
These amino acids may be directly linked to each other by a covalent bond, or covalently linked by a spacer arm. As an example, these amino acids can be linked to each other by a methylene bridge.
Preferably, at least one protomer is covalently linked to another protomer by an intermolecular linkage between the amino acid residue at position 947 of the one protomer and the amino acid at position 776 of the other protomer. These amino acid residues can for example be linked to each other by a methylene bridge attached to a lysine residue at position 947 of the one protomer and to a lysine residue at position 776 of the other protomer.
In particular embodiments of the invention, in at least one protomer, preferably in each protomer, the amino acid residue at position 947 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys947), and in at least another protomer, preferably in each protomer, the amino acid residue at position 776 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys776) and said lysine residue at position 947 of one of said protomers and said lysine residue at position 776 of another one of said protomers are linked by a methylene bridge.
The trimer of the invention can comprise any number and any combination of the intermolecular covalent linkages described above.
These covalent intermolecular linkages may for example be obtained by treating a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer with formaldehyde.
Date Recue/Date Received 2022-06-15
More particularly, the amino acid residue corresponding to the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein (SEQ ID No: 1) of one of the protomers is covalently linked to the amino acid residue corresponding to the amino acid residue at position 776 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID
No: 1) of another one of the protomers. This additional cross-linking between at least two protomers of the trimer also advantageously stabilizes the trimer.
These amino acids may be directly linked to each other by a covalent bond, or covalently linked by a spacer arm. As an example, these amino acids can be linked to each other by a methylene bridge.
Preferably, at least one protomer is covalently linked to another protomer by an intermolecular linkage between the amino acid residue at position 947 of the one protomer and the amino acid at position 776 of the other protomer. These amino acid residues can for example be linked to each other by a methylene bridge attached to a lysine residue at position 947 of the one protomer and to a lysine residue at position 776 of the other protomer.
In particular embodiments of the invention, in at least one protomer, preferably in each protomer, the amino acid residue at position 947 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys947), and in at least another protomer, preferably in each protomer, the amino acid residue at position 776 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue (Lys776) and said lysine residue at position 947 of one of said protomers and said lysine residue at position 776 of another one of said protomers are linked by a methylene bridge.
The trimer of the invention can comprise any number and any combination of the intermolecular covalent linkages described above.
These covalent intermolecular linkages may for example be obtained by treating a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer with formaldehyde.
Date Recue/Date Received 2022-06-15
14 The inventors have discovered that, surprisingly, these covalent intermolecular linkages stabilize the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer, advantageously in the closed RBD-down conformation, over a long period, preventing conformational changes leading to the post-fusion conformation, while not preventing antibodies production and not masking the epitopes recognized by the antibodies. Therefore, the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention enables the production of antibodies recognizing the tridimensional epitopes of the native protein.
The trimer of the invention can also comprise additional covalent linkages, in particular via methylene bridges, which may be intermolecular or intramolecular linkages. These additional linkages can be between the above-mentioned amino acid residues, between such residues and other amino acid residues, or between other amino acid residues.
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, one, two or the three protomers can comprise C-terminal and/or N-terminal modification(s).
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers is linked to a C-terminal trimerization domain, which increases its stability in the trimer form, for example a C-terminal T4 fibritin trimerization domain, or any other domain known by the person skilled in the art for its capacity of triggering and/or stabilizing trimerization of a protein to which it is linked.
In preferred embodiments of the invention, each protomer comprises, at its C-terminal end, a C-terminal T4 fibritin trimerization motif, also known as Foldon domain, of amino acid sequence GYIPEAPRDGQAYVRKDGEVVVLLSTFL (SEQ
ID No: 4), consisting of an extended N-terminal region (G1-Q11), a p-hairpin (Al2-L23), and a C-terminal 310 helix (L23¨L27). The extended N-terminal region contains a polyproline II helix between residues P4 and P7 and packs against one side of the p-hairpin by hydrophobic contacts.
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers comprises at least two proline substitutions at amino acid residues corresponding to the amino acid residues at positions 986 and 987 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein Date Recue/Date Received 2022-06-15
The trimer of the invention can also comprise additional covalent linkages, in particular via methylene bridges, which may be intermolecular or intramolecular linkages. These additional linkages can be between the above-mentioned amino acid residues, between such residues and other amino acid residues, or between other amino acid residues.
In the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention, one, two or the three protomers can comprise C-terminal and/or N-terminal modification(s).
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers is linked to a C-terminal trimerization domain, which increases its stability in the trimer form, for example a C-terminal T4 fibritin trimerization domain, or any other domain known by the person skilled in the art for its capacity of triggering and/or stabilizing trimerization of a protein to which it is linked.
In preferred embodiments of the invention, each protomer comprises, at its C-terminal end, a C-terminal T4 fibritin trimerization motif, also known as Foldon domain, of amino acid sequence GYIPEAPRDGQAYVRKDGEVVVLLSTFL (SEQ
ID No: 4), consisting of an extended N-terminal region (G1-Q11), a p-hairpin (Al2-L23), and a C-terminal 310 helix (L23¨L27). The extended N-terminal region contains a polyproline II helix between residues P4 and P7 and packs against one side of the p-hairpin by hydrophobic contacts.
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers comprises at least two proline substitutions at amino acid residues corresponding to the amino acid residues at positions 986 and 987 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein Date Recue/Date Received 2022-06-15
15 (SEQ ID No: 1). These proline substitutions increase the stability of the trimer in its native conformation in the cells.
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers comprises two to four additional proline substitutions, preferably at amino acid residues corresponding to the amino acid residues at positions 817, 892, 899 and/or 942 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1). These additional proline substitutions increase even more the stability of the trimer in its native conformation in the cells.
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers is linked, preferably at its C-terminal end, to at least one tag, such as a twin Strep-tag and/or a polyhistidine tag (for example of eight successive histidine residues), for facilitating its purification.
The twin Strep-tag consists of two spaced apart identical amino acid sequences of sequence WSHPQFEK (SEQ ID No: 5) and has the capacity of specifically binding to a specifically engineered streptavidin.
Each protomer may further comprise, between the C-terminal trimerization motif and the one or several tags, a cleavage site such as a HRV3C protease cleavage site, of sequence LEVLFQGP (SEQ ID No: 6).
A recombinant SARS-CoV-2 S glycoprotein ectodomain trimer according to the invention can comprise at least one, preferably two, and more preferably three, protomers comprising the amino acid sequence of sequence SEQ ID No: 7.
In particular embodiments, at least one, preferably two, and more preferably each, of the protomers consists of an amino acid sequence of sequence SEQ ID
No: 8.
Method of producing the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer A method of producing a trimer according to the invention comprises:
- expressing nucleic acid molecule(s) encoding the recombinant protomer(s) of the invention, as defined above, in a host cell to produce a trimer of such protomer(s), - purifying this trimer, and - treating this trimer with formaldehyde.
Date Recue/Date Received 2022-06-15
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers comprises two to four additional proline substitutions, preferably at amino acid residues corresponding to the amino acid residues at positions 817, 892, 899 and/or 942 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1). These additional proline substitutions increase even more the stability of the trimer in its native conformation in the cells.
In particular embodiments of the invention, at least one, preferably two, and more preferably each, of the protomers is linked, preferably at its C-terminal end, to at least one tag, such as a twin Strep-tag and/or a polyhistidine tag (for example of eight successive histidine residues), for facilitating its purification.
The twin Strep-tag consists of two spaced apart identical amino acid sequences of sequence WSHPQFEK (SEQ ID No: 5) and has the capacity of specifically binding to a specifically engineered streptavidin.
Each protomer may further comprise, between the C-terminal trimerization motif and the one or several tags, a cleavage site such as a HRV3C protease cleavage site, of sequence LEVLFQGP (SEQ ID No: 6).
A recombinant SARS-CoV-2 S glycoprotein ectodomain trimer according to the invention can comprise at least one, preferably two, and more preferably three, protomers comprising the amino acid sequence of sequence SEQ ID No: 7.
In particular embodiments, at least one, preferably two, and more preferably each, of the protomers consists of an amino acid sequence of sequence SEQ ID
No: 8.
Method of producing the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer A method of producing a trimer according to the invention comprises:
- expressing nucleic acid molecule(s) encoding the recombinant protomer(s) of the invention, as defined above, in a host cell to produce a trimer of such protomer(s), - purifying this trimer, and - treating this trimer with formaldehyde.
Date Recue/Date Received 2022-06-15
16 The first step of this method is the production of the three protomers containing at least the SARS-CoV-2 S glycoprotein ectodomain by genetic recombination.
This step can be carried out by any manner known to the person skilled in the art, in particular using an expression vector comprising nucleic acid molecules encoding these protomers. When all the protomers are identical, only one such nucleic acid molecule is required.
The expression vector can be of any type known per se for use in genetic engineering, in particular a plasmid, a cosmid, a virus, a bacteriophage, containing the necessary elements for the transcription and translation of the sequence(s) encoding the protomer(s) according to the invention. It can comprise in particular the following elements, functionally linked, for each protomer: a promoter located 5' of a nucleotide sequence coding for the protomer according to the invention, and transcription termination signals 3' of this sequence.
The host cell can be any cell in which a nucleic acid molecule can be expressed.
This host cell can equally well be a prokaryotic cell, in particular bacterial, particularly for the mass production of the protomer(s), or a eukaryotic cell, which can be of lower or higher eucaryote, for example of yeast, invertebrates or mammals. The host cell may express the protomer(s) of the invention in a stable, inducible or constitutive manner, or else in a transient manner. As an example, the nucleic acid molecule(s) encoding the protomer(s) of the invention can be transiently expressed in human embryonic kidney cell lines.
The host cell is cultured under conditions enabling the expression and the recovery of the protomer(s) thus produced, which are naturally assembled in a trimer form. It is within the skills of the person skilled in the art to determine such culture conditions, according to the cell type.
The trimer thus obtained may be purified by any method known per se. In the particular embodiments of the invention wherein at least one of the recombinant protomers comprises a tag, in particular at its C-terminal end, such as a poly-histidine tag, the purification method can take advantage of the specific capacity of this tag to bind a binding partner, for example Sepharose resin in the case of the poly-histidine tag.
The step of treating the trimer with formaldehyde is carried out in conditions Date Recue/Date Received 2022-06-15
This step can be carried out by any manner known to the person skilled in the art, in particular using an expression vector comprising nucleic acid molecules encoding these protomers. When all the protomers are identical, only one such nucleic acid molecule is required.
The expression vector can be of any type known per se for use in genetic engineering, in particular a plasmid, a cosmid, a virus, a bacteriophage, containing the necessary elements for the transcription and translation of the sequence(s) encoding the protomer(s) according to the invention. It can comprise in particular the following elements, functionally linked, for each protomer: a promoter located 5' of a nucleotide sequence coding for the protomer according to the invention, and transcription termination signals 3' of this sequence.
The host cell can be any cell in which a nucleic acid molecule can be expressed.
This host cell can equally well be a prokaryotic cell, in particular bacterial, particularly for the mass production of the protomer(s), or a eukaryotic cell, which can be of lower or higher eucaryote, for example of yeast, invertebrates or mammals. The host cell may express the protomer(s) of the invention in a stable, inducible or constitutive manner, or else in a transient manner. As an example, the nucleic acid molecule(s) encoding the protomer(s) of the invention can be transiently expressed in human embryonic kidney cell lines.
The host cell is cultured under conditions enabling the expression and the recovery of the protomer(s) thus produced, which are naturally assembled in a trimer form. It is within the skills of the person skilled in the art to determine such culture conditions, according to the cell type.
The trimer thus obtained may be purified by any method known per se. In the particular embodiments of the invention wherein at least one of the recombinant protomers comprises a tag, in particular at its C-terminal end, such as a poly-histidine tag, the purification method can take advantage of the specific capacity of this tag to bind a binding partner, for example Sepharose resin in the case of the poly-histidine tag.
The step of treating the trimer with formaldehyde is carried out in conditions Date Recue/Date Received 2022-06-15
17 enabling the formation of intramolecular methylene bridges between the protomers, for example:
- between an amino acid residue at position 408, preferably Arg408, and an amino acid residue at position 378, preferably Lys378, - and between an amino acid residue at position 947, preferably Lys947, and an amino acid residue at position 1019, preferably Arg1019, and/or between an amino acid residue at position 947, preferably Lys947, and an amino acid residue at position 776, preferably Lys 776.
It is preferably carried out for several hours, at least for 2 hours, and preferably overnight in order to obtain a complete crosslinking between the protomers. It can be carried out at room temperature, i.e., at a temperature of between 20 and 25 C.
As an example, the step of treating the trimer with formaldehyde comprises contacting the trimer with an aqueous solution comprising 4 % v/v of formaldehyde. The content of protein introduced in this aqueous solution is preferably comprised between 0.3 and 1.2 mg/ml. It is for example of about 1 mg/ml.
Proteoliposomes A proteoliposome according to the invention comprises a lipid vesicle a surface of which is coated by a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer according to the invention.
Such a proteoliposome, preferably of defined lipid composition, advantageously resembles a virus-like particle and provides increased stability and prolonged circulating half-life in vivo of the recombinant trimer. Used as a vaccine, the proteoliposome of the invention induces more efficient immunes responses than immunization with the sole recombinant trimer of the invention.
The lipid vesicle may be of any type known per se for an administration to a living being, for example a human being, in particular as a vaccine.
In particular embodiments of the invention, the lipid vesicle comprises a mixture of L-a-phosphatidylcholine, cholesterol and a polyhistidine-tag conjugating lipid, in particular 56 to 61 % by weight of L-a-phosphatidylcholine, 34 to 36 % by weight of cholesterol and 3 to 10 % by weight of a polyhistidine-tag conjugating lipid, for example 60 % by weight of L-a-phosphatidylcholine, 36 % by weight of Date Recue/Date Received 2022-06-15
- between an amino acid residue at position 408, preferably Arg408, and an amino acid residue at position 378, preferably Lys378, - and between an amino acid residue at position 947, preferably Lys947, and an amino acid residue at position 1019, preferably Arg1019, and/or between an amino acid residue at position 947, preferably Lys947, and an amino acid residue at position 776, preferably Lys 776.
It is preferably carried out for several hours, at least for 2 hours, and preferably overnight in order to obtain a complete crosslinking between the protomers. It can be carried out at room temperature, i.e., at a temperature of between 20 and 25 C.
As an example, the step of treating the trimer with formaldehyde comprises contacting the trimer with an aqueous solution comprising 4 % v/v of formaldehyde. The content of protein introduced in this aqueous solution is preferably comprised between 0.3 and 1.2 mg/ml. It is for example of about 1 mg/ml.
Proteoliposomes A proteoliposome according to the invention comprises a lipid vesicle a surface of which is coated by a recombinant SARS-CoV-2 S glycoprotein ectodomain trimer according to the invention.
Such a proteoliposome, preferably of defined lipid composition, advantageously resembles a virus-like particle and provides increased stability and prolonged circulating half-life in vivo of the recombinant trimer. Used as a vaccine, the proteoliposome of the invention induces more efficient immunes responses than immunization with the sole recombinant trimer of the invention.
The lipid vesicle may be of any type known per se for an administration to a living being, for example a human being, in particular as a vaccine.
In particular embodiments of the invention, the lipid vesicle comprises a mixture of L-a-phosphatidylcholine, cholesterol and a polyhistidine-tag conjugating lipid, in particular 56 to 61 % by weight of L-a-phosphatidylcholine, 34 to 36 % by weight of cholesterol and 3 to 10 % by weight of a polyhistidine-tag conjugating lipid, for example 60 % by weight of L-a-phosphatidylcholine, 36 % by weight of Date Recue/Date Received 2022-06-15
18 cholesterol and 4 % by weight of a polyhistidine-tag conjugating lipid.
The polyhistidine-tag conjugating lipid can for example be a lipid modified by chelator immobilizing a metal cation, such as a nickel or a cobalt cation. The product marketed by AvantiO Polar Lipids under the name DGS-NTA-(Ni2+) (1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl]
(nickel salt)) can for example be used.
Alternatively, cobalt porphyrin phospholipids (CoPoP) incorporated into lipid bilayers can be used to attach polyhistidine-tagged glycoproteins (Federizon et al, 2021, Pharmaceutics, 13, 98), more particularly, in the context of the invention, the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention.
Method of preparing the proteoliposomes A method of preparing proteoliposomes according to the invention comprises incubating the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention with the lipid vesicle, so as to ensure immobilization of the trimer on the surface of the lipid vesicle by non-covalent interactions.
This incubation is preferably carried out for at least 6 hours, preferably from 12 to 24 hours, and preferably at a temperature of between 20 and 25 C.
The ratio trimer/lipid vesicle is preferably chosen so as to have a sufficient excess of protein to saturate the lipid vesicles, more particularly at least 2 times of excess protein. The ratio trimer/lipid vesicle is preferably comprised between 2:1 w/w and 4:1 w/w. It is for example equal to 3:1 w:w.
Alternatively, the recombinant trimer of the invention can be covalently linked to the surface of the lipid vesicle, for example by reacting at least a cysteine residue of at least a protomer of the trimer, preferably a cysteine residue situated in a C-terminal part of the protomer, with a group carried by the lipid vesicle, capable of reacting with a sulfhydryl group.
The method may comprise a final step of purifying the proteoliposome obtained.
Vaccine A vaccine according to the invention comprises proteoliposomes such as defined above, and, optionally, a pharmaceutically acceptable carrier and/or an adjuvant.
The pharmaceutically acceptable carrier can consist of any conventional carrier, in particular in the field of vaccine compositions. It is for example a liquid aqueous Date Recue/Date Received 2022-06-15
The polyhistidine-tag conjugating lipid can for example be a lipid modified by chelator immobilizing a metal cation, such as a nickel or a cobalt cation. The product marketed by AvantiO Polar Lipids under the name DGS-NTA-(Ni2+) (1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl]
(nickel salt)) can for example be used.
Alternatively, cobalt porphyrin phospholipids (CoPoP) incorporated into lipid bilayers can be used to attach polyhistidine-tagged glycoproteins (Federizon et al, 2021, Pharmaceutics, 13, 98), more particularly, in the context of the invention, the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention.
Method of preparing the proteoliposomes A method of preparing proteoliposomes according to the invention comprises incubating the recombinant SARS-CoV-2 S glycoprotein ectodomain trimer of the invention with the lipid vesicle, so as to ensure immobilization of the trimer on the surface of the lipid vesicle by non-covalent interactions.
This incubation is preferably carried out for at least 6 hours, preferably from 12 to 24 hours, and preferably at a temperature of between 20 and 25 C.
The ratio trimer/lipid vesicle is preferably chosen so as to have a sufficient excess of protein to saturate the lipid vesicles, more particularly at least 2 times of excess protein. The ratio trimer/lipid vesicle is preferably comprised between 2:1 w/w and 4:1 w/w. It is for example equal to 3:1 w:w.
Alternatively, the recombinant trimer of the invention can be covalently linked to the surface of the lipid vesicle, for example by reacting at least a cysteine residue of at least a protomer of the trimer, preferably a cysteine residue situated in a C-terminal part of the protomer, with a group carried by the lipid vesicle, capable of reacting with a sulfhydryl group.
The method may comprise a final step of purifying the proteoliposome obtained.
Vaccine A vaccine according to the invention comprises proteoliposomes such as defined above, and, optionally, a pharmaceutically acceptable carrier and/or an adjuvant.
The pharmaceutically acceptable carrier can consist of any conventional carrier, in particular in the field of vaccine compositions. It is for example a liquid aqueous Date Recue/Date Received 2022-06-15
19 carrier.
Any adjuvant capable of enhancing an immune response of the host can be contained in the vaccine of the invention. Examples of adjuvants are based on monophosphoryl lipid A (MPLA) and aluminum salt, for example aluminum hydroxide or aluminum phosphate, such as AS504, or on squalene, such as MF59.
The vaccine according to the invention can furthermore contain any conventional additive known per se, as well as optionally other active substances.
As additives that can be used in the vaccine according to the invention, mention can be made of excipients, diluents, surfactants, in particular of polysorbate type, stabilizing agents, etc.
The vaccine according to the invention can be formulated in any dosage form suitable for administration to a mammal, in particular to a human subject. It is preferably formulated in a dosage form suitable for parenteral administration.
In particular, it can be formulated in a dosage form suitable for intramuscular, intravenous, intraperitoneal or subcutaneous injection, or for administration by the intranasal route or by inhalation. It is for example formulated as a solution for injection or as a formulation for spray.
The vaccine of the invention can be conditioned in monodose form or in multidose form, for example in a five-dose vial. In particular embodiments of the invention, a unit dose of the vaccine comprises 50 to 100 pg of proteoliposomes of the invention.
Use of the vaccine for treating or preventing a SARS-CoV-2 infection in a subject The vaccine of the invention can be used for treating or preventing a SARS-CoV-2 infection in a subject, by administering the vaccine of the invention to this subject, preferably in a therapeutically effective amount, so as to induce an immune response to the SARS-CoV-2 glycoprotein S ectodomain.
The subject is preferably a mammal, in particular a human subject.
The vaccine of the invention can be used to treat any subject in need thereof, in particular any subject suffering from a SARS-CoV-2 infection, or, by way of prevention, any non-affected subject likely to contract such an infection.
In particular, it has been discovered by the inventors that immunization of cynomolgus macaques with the vaccine of the invention induces high antibody Date Recue/Date Received 2022-06-15
Any adjuvant capable of enhancing an immune response of the host can be contained in the vaccine of the invention. Examples of adjuvants are based on monophosphoryl lipid A (MPLA) and aluminum salt, for example aluminum hydroxide or aluminum phosphate, such as AS504, or on squalene, such as MF59.
The vaccine according to the invention can furthermore contain any conventional additive known per se, as well as optionally other active substances.
As additives that can be used in the vaccine according to the invention, mention can be made of excipients, diluents, surfactants, in particular of polysorbate type, stabilizing agents, etc.
The vaccine according to the invention can be formulated in any dosage form suitable for administration to a mammal, in particular to a human subject. It is preferably formulated in a dosage form suitable for parenteral administration.
In particular, it can be formulated in a dosage form suitable for intramuscular, intravenous, intraperitoneal or subcutaneous injection, or for administration by the intranasal route or by inhalation. It is for example formulated as a solution for injection or as a formulation for spray.
The vaccine of the invention can be conditioned in monodose form or in multidose form, for example in a five-dose vial. In particular embodiments of the invention, a unit dose of the vaccine comprises 50 to 100 pg of proteoliposomes of the invention.
Use of the vaccine for treating or preventing a SARS-CoV-2 infection in a subject The vaccine of the invention can be used for treating or preventing a SARS-CoV-2 infection in a subject, by administering the vaccine of the invention to this subject, preferably in a therapeutically effective amount, so as to induce an immune response to the SARS-CoV-2 glycoprotein S ectodomain.
The subject is preferably a mammal, in particular a human subject.
The vaccine of the invention can be used to treat any subject in need thereof, in particular any subject suffering from a SARS-CoV-2 infection, or, by way of prevention, any non-affected subject likely to contract such an infection.
In particular, it has been discovered by the inventors that immunization of cynomolgus macaques with the vaccine of the invention induces high antibody Date Recue/Date Received 2022-06-15
20 titers with potent neutralizing activity against the vaccine strain, alpha, beta and gamma variants as well as TH1 CD4+ biased T cell responses. High titers are already induced after two immunizations, with a median ID50 of about 8000 two weeks after the second immunization. Furthermore, although anti-RBD specific antibody responses are initially predominant, the third immunization boosts significant non-RBD antibody titers. Four weeks after the third immunization, median S-specific ED50s are 3 times higher than RBD-specific ED50s. This trend is continued after the fourth immunization which reveals a 3.5 times higher median ID50 for S than for RBD five weeks post immunization. These results show that more than two immunizations allow to expand the reactive B cell repertoire that target non-RBD S epitopes. Furthermore, challenging of vaccinated animals with SARS-CoV-2 shows complete protection through sterilizing immunity. In particular, no signs of virus replication can be detected in the upper and lower respiratory tracts consistent with the absence of clinical signs of infection such as lymphopenia and lung damage characteristics for Covid-19 disease. Significant IgG and IgA are detected in nasopharyngeal fluids at the time of viral challenge, showing that administration of the vaccine of the invention induces sterilizing protection by eliciting mucosal immune responses.
Therefore, the vaccine of the invention is efficient and safe.
This administration of the vaccine of the invention can be carried out by any route. It is preferably carried out by a parenteral route, in particular by injection or spray.
In particularly preferred embodiments of the invention, the vaccine is administrated to the subject intramuscularly or intranasally.
Alternatively, it can be administered to the subject by intravenous, intraperitoneal, intraarterial or subcutaneous injection, or by inhalation.
The vaccine of the invention can be administered to the subject in a single dose, or in several doses, in particular administered several days apart.
The therapeutically effective dose and the number of administered doses are dependent on the subject, in particular on its age, weight, symptoms, etc.
Determining the exact administration conditions is within the remit of the practitioner.
For example, each administration is carried out to deliver between 50 and 100 pg Date Recue/Date Received 2022-06-15
Therefore, the vaccine of the invention is efficient and safe.
This administration of the vaccine of the invention can be carried out by any route. It is preferably carried out by a parenteral route, in particular by injection or spray.
In particularly preferred embodiments of the invention, the vaccine is administrated to the subject intramuscularly or intranasally.
Alternatively, it can be administered to the subject by intravenous, intraperitoneal, intraarterial or subcutaneous injection, or by inhalation.
The vaccine of the invention can be administered to the subject in a single dose, or in several doses, in particular administered several days apart.
The therapeutically effective dose and the number of administered doses are dependent on the subject, in particular on its age, weight, symptoms, etc.
Determining the exact administration conditions is within the remit of the practitioner.
For example, each administration is carried out to deliver between 50 and 100 pg Date Recue/Date Received 2022-06-15
21 of proteoliposomes of the invention to the subject.
Preferably, the use of the vaccine of the invention comprises administering a therapeutically effective amount of the vaccine at least twice to the subject.
The two administration steps are preferably spaced apart by a period of between 2 and 8 weeks.
In particular embodiments of the invention, the use of the vaccine of the invention comprises administering a therapeutically effective amount of the vaccine at least three times to the subject. As indicated above, a third immunization advantageously boosts significant non-RBD antibody titers.
Alternatively, the vaccine of the invention can be administrated to a subject after two administrations of other anti-SARS-CoV-2 vaccine(s).
An aspect of the invention relates to a method of treating or preventing a SARS-CoV-2 infection in a subject, comprising administering a vaccine according to the invention to this subject. This method may respond to any of the features described above in relation with the use of the vaccine of the invention for treating or preventing a SARS-CoV-2 infection in a subject.
EXAMPLES
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines HEK293T (ATCC CRL-11268) and HEK293F (Thermo Fisher Scientific) are human embryonic kidney cell lines. HEK293F cells are adapted to grow in suspension. HEK293F cells were cultured at 37 C with 8% CO2 and shaking at 125 rpm in 293FreeStyle expression medium (Life Technologies). HEK293T
cells were cultured at 37 C with 5% CO2 in flasks with DMEM supplemented with 10% fetal bovine serum (FBS), streptomycin (100 pg/mL) and penicillin (100 U/mL). HEK293T/ACE2 cells are a human embryonic kidney cell line expressing human angiotensin-converting enzyme 2. HEK293T/ACE2 cells were cultured at 37 C with 5% CO2 in flasks with DMEM supplemented with 10% FBS, streptomycin (100 pg/mL) and penicillin (100 U/mL). VeroE6 cells (ATCC CRL-1586) are a kidney epithelial cells from African green monkeys. VeroE6 cells were cultured at 37 C with 5% CO2 in DMEM supplemented with or without streptomycin (100 pg/m L) and penicillin (100 U/mL) and with or without 5 or 10%
FBS, and with or without TPCK-trypsin. PBMC were isolated from macaque sera Date Recue/Date Received 2022-06-15
Preferably, the use of the vaccine of the invention comprises administering a therapeutically effective amount of the vaccine at least twice to the subject.
The two administration steps are preferably spaced apart by a period of between 2 and 8 weeks.
In particular embodiments of the invention, the use of the vaccine of the invention comprises administering a therapeutically effective amount of the vaccine at least three times to the subject. As indicated above, a third immunization advantageously boosts significant non-RBD antibody titers.
Alternatively, the vaccine of the invention can be administrated to a subject after two administrations of other anti-SARS-CoV-2 vaccine(s).
An aspect of the invention relates to a method of treating or preventing a SARS-CoV-2 infection in a subject, comprising administering a vaccine according to the invention to this subject. This method may respond to any of the features described above in relation with the use of the vaccine of the invention for treating or preventing a SARS-CoV-2 infection in a subject.
EXAMPLES
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines HEK293T (ATCC CRL-11268) and HEK293F (Thermo Fisher Scientific) are human embryonic kidney cell lines. HEK293F cells are adapted to grow in suspension. HEK293F cells were cultured at 37 C with 8% CO2 and shaking at 125 rpm in 293FreeStyle expression medium (Life Technologies). HEK293T
cells were cultured at 37 C with 5% CO2 in flasks with DMEM supplemented with 10% fetal bovine serum (FBS), streptomycin (100 pg/mL) and penicillin (100 U/mL). HEK293T/ACE2 cells are a human embryonic kidney cell line expressing human angiotensin-converting enzyme 2. HEK293T/ACE2 cells were cultured at 37 C with 5% CO2 in flasks with DMEM supplemented with 10% FBS, streptomycin (100 pg/mL) and penicillin (100 U/mL). VeroE6 cells (ATCC CRL-1586) are a kidney epithelial cells from African green monkeys. VeroE6 cells were cultured at 37 C with 5% CO2 in DMEM supplemented with or without streptomycin (100 pg/m L) and penicillin (100 U/mL) and with or without 5 or 10%
FBS, and with or without TPCK-trypsin. PBMC were isolated from macaque sera Date Recue/Date Received 2022-06-15
22 and cultured in RPMI1640 GlutaMAX0 medium (Gibco0) supplemented with 10% FBS.
Viruses SARS-CoV-2 virus (hCoV-19/France/ IDF0372/2020 strain) was isolated by the National Reference Center for Respiratory Viruses (Institut Pasteur, Paris, France) as described in Lescure etal. (2020). Lancet Infect Dis 20, 697-706, and produced by two passages on Vero E6 cells in DMEM (Dulbecco's Modified Eagles Medium) without FBS, supplemented with 1% P/S (penicillin at 10,000 U.m1-1 and streptomycin at 10,000 pg.m1-1) and 1 pg.m1-1TPCK-trypsin at 37 C in a humidified CO2 incubator and titrated on Vero E6 cells. Whole genome sequencing was performed with no modifications observed compared with the initial specimen and sequences were deposited after assembly on the GISAID
EpiCoV platform under accession number ID EPLISL_410720.
Ethics and biosafetv statement Cynomolgus macaques (Macaca fascicularis) originating from Mauritian AAALAC certified breeding centers, described in Table 1, were used in this study.
MF1-MF4 are in the vaccinated group and MF5-MF8 in the control group.
Age Weight at Day 0 Developmental Name Gender Date of birth (years) post exposure (kg) stage MF1 M 04/04/2017 3,68 3,96 Young adult MF2 M 05/04/2017 3,68 4,52 Young adult MF3 M 10/04/2017 3,67 4,98 Young adult MF4 M 12/04/2017 3,66 6,39 Young adult MF5 M 27/04/2017 3,62 3,64 Young adult MF6 M 27/04/2017 3,62 4,29 Young adult MF7 M 12/05/2017 3,58 3,14 Young adult MF8 M 15/05/2017 3,57 3,91 Young adult Table 1 All animals were housed in IDMIT infrastructure facilities (CEA, Fontenay-aux-roses), under BSL-2 and BSL-3 containment when necessary (Animal facility authorization #D92-032-02, Prefecture des Hauts de Seine, France) and in compliance with European Directive 2010/63/EU, the French regulations and the Date Recue/Date Received 2022-06-15
Viruses SARS-CoV-2 virus (hCoV-19/France/ IDF0372/2020 strain) was isolated by the National Reference Center for Respiratory Viruses (Institut Pasteur, Paris, France) as described in Lescure etal. (2020). Lancet Infect Dis 20, 697-706, and produced by two passages on Vero E6 cells in DMEM (Dulbecco's Modified Eagles Medium) without FBS, supplemented with 1% P/S (penicillin at 10,000 U.m1-1 and streptomycin at 10,000 pg.m1-1) and 1 pg.m1-1TPCK-trypsin at 37 C in a humidified CO2 incubator and titrated on Vero E6 cells. Whole genome sequencing was performed with no modifications observed compared with the initial specimen and sequences were deposited after assembly on the GISAID
EpiCoV platform under accession number ID EPLISL_410720.
Ethics and biosafetv statement Cynomolgus macaques (Macaca fascicularis) originating from Mauritian AAALAC certified breeding centers, described in Table 1, were used in this study.
MF1-MF4 are in the vaccinated group and MF5-MF8 in the control group.
Age Weight at Day 0 Developmental Name Gender Date of birth (years) post exposure (kg) stage MF1 M 04/04/2017 3,68 3,96 Young adult MF2 M 05/04/2017 3,68 4,52 Young adult MF3 M 10/04/2017 3,67 4,98 Young adult MF4 M 12/04/2017 3,66 6,39 Young adult MF5 M 27/04/2017 3,62 3,64 Young adult MF6 M 27/04/2017 3,62 4,29 Young adult MF7 M 12/05/2017 3,58 3,14 Young adult MF8 M 15/05/2017 3,57 3,91 Young adult Table 1 All animals were housed in IDMIT infrastructure facilities (CEA, Fontenay-aux-roses), under BSL-2 and BSL-3 containment when necessary (Animal facility authorization #D92-032-02, Prefecture des Hauts de Seine, France) and in compliance with European Directive 2010/63/EU, the French regulations and the Date Recue/Date Received 2022-06-15
23 Standards for Human Care and Use of Laboratory Animals, of the Office for Laboratory Animal Welfare (OLAW, assurance number #A5826-01, US). The protocols were approved by the institutional ethical committee "Comite d'Ethique en Experimentation Animale du Commissariat a l'Energie Atomique et aux Energies Alternatives" (CEtEA #44) under statement number A20-011. The study was authorized by the "Research, Innovation and Education Ministry"
under registration number APAFIS#24434-2020030216532863.
Animals and study design Cynomolgus macaques were randomly assigned in two experimental groups.
The vaccinated group (n = 4) received 50 pg of proteoliposomes of the invention (SARSCoV-2 S-LV) adjuvanted with 500 pg of MPLA liposomes (Polymun Scientific) diluted in PBS at weeks 0, 4, 8 and 19, while control animals (n =
4) received no vaccination. Vaccinated animals were sampled in blood at weeks 0, 2, 4, 6, 8, 11, 12, 14, 19, 21 and 22. At week 24, all animals were exposed to a total dose of 105 pfu of SARS-CoV-2 virus (hCoV-19/France/ IDF0372/2020 strain; GISAID EpiCoV platform under accession number EPI_ISL_410720) via the combination of intranasal and intra-tracheal routes (0,25 mL in each nostril and 4,5 mL in the trachea, i.e., a total of 5 mL; day 0), using atropine (0.04 mg/kg) for pre-medication and ketamine (5 mg/kg) with medetomidine (0.042 mg/kg) for anesthesia. Nasopharyngeal, tracheal and rectal swabs, were collected at days 2, 3, 4, 6, 7, 10, 14 and 27 days post exposure (dpe) while blood was taken at days 2, 4, 7, 10, 14 and 27 dpe. Bronchoalveolar lavages (BAL) were performed using 50 mL sterile saline on 3 and 7 dpe. Chest CT was performed at 3, 7, 10 and 14 dpe in anesthetized animals using tiletamine (4 mg.kg-1) and zolazepam (4 mg.kg-1). Blood cell counts, haemoglobin, and haematocrit, were determined from EDTA blood using a DHX800 analyzer (Beckman Coulter).
Methods details Protein expression and purification The gene of nucleotide sequence SEQ ID No: 9, encoding for a protein/protomer of amino acid sequence SEQ ID No: 8, corresponding to residues 1-1208 of the native SARS-CoV-2 S glycoprotein with proline substitutions at residues 986 and 987 ("2P"), a "GSAS" (SEQ ID No: 2) substitution at the furin cleavage site (residues 682-685), and linked at its C-terminal end to, successively: a T4 fibritin Date Recue/Date Received 2022-06-15
under registration number APAFIS#24434-2020030216532863.
Animals and study design Cynomolgus macaques were randomly assigned in two experimental groups.
The vaccinated group (n = 4) received 50 pg of proteoliposomes of the invention (SARSCoV-2 S-LV) adjuvanted with 500 pg of MPLA liposomes (Polymun Scientific) diluted in PBS at weeks 0, 4, 8 and 19, while control animals (n =
4) received no vaccination. Vaccinated animals were sampled in blood at weeks 0, 2, 4, 6, 8, 11, 12, 14, 19, 21 and 22. At week 24, all animals were exposed to a total dose of 105 pfu of SARS-CoV-2 virus (hCoV-19/France/ IDF0372/2020 strain; GISAID EpiCoV platform under accession number EPI_ISL_410720) via the combination of intranasal and intra-tracheal routes (0,25 mL in each nostril and 4,5 mL in the trachea, i.e., a total of 5 mL; day 0), using atropine (0.04 mg/kg) for pre-medication and ketamine (5 mg/kg) with medetomidine (0.042 mg/kg) for anesthesia. Nasopharyngeal, tracheal and rectal swabs, were collected at days 2, 3, 4, 6, 7, 10, 14 and 27 days post exposure (dpe) while blood was taken at days 2, 4, 7, 10, 14 and 27 dpe. Bronchoalveolar lavages (BAL) were performed using 50 mL sterile saline on 3 and 7 dpe. Chest CT was performed at 3, 7, 10 and 14 dpe in anesthetized animals using tiletamine (4 mg.kg-1) and zolazepam (4 mg.kg-1). Blood cell counts, haemoglobin, and haematocrit, were determined from EDTA blood using a DHX800 analyzer (Beckman Coulter).
Methods details Protein expression and purification The gene of nucleotide sequence SEQ ID No: 9, encoding for a protein/protomer of amino acid sequence SEQ ID No: 8, corresponding to residues 1-1208 of the native SARS-CoV-2 S glycoprotein with proline substitutions at residues 986 and 987 ("2P"), a "GSAS" (SEQ ID No: 2) substitution at the furin cleavage site (residues 682-685), and linked at its C-terminal end to, successively: a T4 fibritin Date Recue/Date Received 2022-06-15
24 trimerization motif (of sequence SEQ ID No: 4), a C-terminal HRV3C protease cleavage site (of sequence SEQ ID No: 6), a 8X-histidine tag and a Twin-Strep-Tag (two spaced-apart repeats of the sequence SEQ ID No: 5), was transiently expressed in human embryonic kidney cell lines FreeStyle293F (Thermo Fisher scientific) using polyethylenimine (PEI) 1 pg/pl for transfection.
Supernatants were harvested five days post-transfection, centrifuged for 30 min at 5000 rpm and filtered using 0.20 m filters (ClearLine0). The trimer ("S") was purified from the supernatant by Ni2+-Sepharose chromatography (Excel purification resin, Cytiva) in buffer A (50 mM HEPES pH 7.4, 200 mM NaCI) and eluted in buffer B (50 mM HEPES pH 7.4, 200 mM NaCI, 500 mM imidazole).
Eluted trimer-containing fractions were concentrated using Amicon0 Ultra (cut-off: 30 KDa) (Millipore) and further purified by size-exclusion chromatography (SEC) on a Superose0 6 column (GE Healthcare) in buffer A or in PBS.
For RBD expression, the following reagent was produced under HH5N272201400008C and obtained through BEI Resources, NIAID, NIH:
Vector pCAGGS containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Receptor Binding Domain (RBD), NR-52309. The SARS-CoV-2 S RBD domain (residues 319 to 541) was expressed in EXPI293 cells by transient transfection according to the manufacturer's protocol (Thermo Fisher Scientific). Supernatants were harvested five days after transfection and cleared by centrifugation. The supernatant was passed through a 0.45 pm filter and RBD
was purified using Ni2+-chromatography (HisTrap HP column, GE Healthcare) in buffer C (20 mM Tris pH 7.5 and 150 mM NaCI buffer) followed by a washing step with buffer D (20 mM Tris pH 7.5 and 150 mM NaCI buffer, 75 mM imidazole) and elution with buffer E (20 mM Tris pH 7.5 and 150 mM NaCI buffer, 500 mM
imidazole). Eluted RBD was further purified by SEC on a Superdex 75 column (GE Healthcare) in buffer C. Protein concentrations were determined using an absorption coefficient (A1%,1cm) at 280 nm of 10.4 and 13.06 for S protein and RBD, respectively, using ProtParam.
Trimer crosslinking The trimer "S protein" at 1 mg/ml in PBS was cross-linked with 4% formaldehyde (FA) (Sigma) overnight at room temperature. The reaction was stopped with 1 M
Tris HCI pH 7.4 adjusting the sample buffer to 7.5 mM Tris/HCI pH 7.4. FA was Date Recue/Date Received 2022-06-15
Supernatants were harvested five days post-transfection, centrifuged for 30 min at 5000 rpm and filtered using 0.20 m filters (ClearLine0). The trimer ("S") was purified from the supernatant by Ni2+-Sepharose chromatography (Excel purification resin, Cytiva) in buffer A (50 mM HEPES pH 7.4, 200 mM NaCI) and eluted in buffer B (50 mM HEPES pH 7.4, 200 mM NaCI, 500 mM imidazole).
Eluted trimer-containing fractions were concentrated using Amicon0 Ultra (cut-off: 30 KDa) (Millipore) and further purified by size-exclusion chromatography (SEC) on a Superose0 6 column (GE Healthcare) in buffer A or in PBS.
For RBD expression, the following reagent was produced under HH5N272201400008C and obtained through BEI Resources, NIAID, NIH:
Vector pCAGGS containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Receptor Binding Domain (RBD), NR-52309. The SARS-CoV-2 S RBD domain (residues 319 to 541) was expressed in EXPI293 cells by transient transfection according to the manufacturer's protocol (Thermo Fisher Scientific). Supernatants were harvested five days after transfection and cleared by centrifugation. The supernatant was passed through a 0.45 pm filter and RBD
was purified using Ni2+-chromatography (HisTrap HP column, GE Healthcare) in buffer C (20 mM Tris pH 7.5 and 150 mM NaCI buffer) followed by a washing step with buffer D (20 mM Tris pH 7.5 and 150 mM NaCI buffer, 75 mM imidazole) and elution with buffer E (20 mM Tris pH 7.5 and 150 mM NaCI buffer, 500 mM
imidazole). Eluted RBD was further purified by SEC on a Superdex 75 column (GE Healthcare) in buffer C. Protein concentrations were determined using an absorption coefficient (A1%,1cm) at 280 nm of 10.4 and 13.06 for S protein and RBD, respectively, using ProtParam.
Trimer crosslinking The trimer "S protein" at 1 mg/ml in PBS was cross-linked with 4% formaldehyde (FA) (Sigma) overnight at room temperature. The reaction was stopped with 1 M
Tris HCI pH 7.4 adjusting the sample buffer to 7.5 mM Tris/HCI pH 7.4. FA was Date Recue/Date Received 2022-06-15
25 removed by PBS buffer exchange using 30 KDa cut-off concentrators (Amicon0). FA crosslinking was confirmed by separating the formaldehyde-treated trimers "FA-S protein" on a 10% SDS-PAGE under reducing conditions.
Trimer coupling to liposomes Liposomes were prepared as follows.
The liposomes were composed of 60% of L-a-phosphatidylcholine, 4% His tag-conjugating lipid, DGS-NTA-(Ni2+) and 36% cholesterol (Avanti Polar Lipids).
Lipid components were dissolved in chloroform, mixed and placed for two hours in a desiccator under vacuum at room temperature to obtain a lipid film. The film was hydrated in filtered (0.22 pm) PBS and liposomes were prepared by extrusion using membrane filters with a pore size of 0.1 pm (Whatman0 Nuclepore0 Track-Etched membranes). The integrity and size of the liposomes was analyzed by negative staining-EM.
For protein coupling, the liposomes were incubated overnight with FA-S protein or S protein in a 3:1 ratio (w/w).
Free FA-S protein was separated from the FA-S-proteoliposomes (S-LVs) by sucrose gradient (5-40%) centrifugation in a 5W55 rotor at 40,000 rpm for 2 h.
The amount of protein conjugated to the liposomes was determined by Bradford assay and SDS-PAGE densitometry analysis comparing S-LV bands with standard S protein concentrations.
Trimer thermostability Thermal denaturation of S protein, native or FA-cross-linked was analyzed by differential scanning fluorimetry coupled to back scattering using a Prometheus NT.48 instrument (Nanotemper Technologies). Protein samples were first extensively dialyzed against PBS pH 7.4, and the protein concentration was adjusted to 0.3 mg/ml. 10 pL of sample were loaded into the capillary and intrinsic fluorescence was measured at a ramp rate of 1 C/min with an excitation power of 30 %. Protein unfolding was monitored by the changes in fluorescence emission at 350 and 330 nm. The thermal unfolding midpoint (Tm) of the proteins was determined using the Prometheus NT software.
Negative stain electron microscopy Protein samples were visualized by negative-stain electron microscopy (EM) using 3-4 pL aliquots containing 0.1-0.2 mg/ml of protein. Samples were applied Date Recue/Date Received 2022-06-15
Trimer coupling to liposomes Liposomes were prepared as follows.
The liposomes were composed of 60% of L-a-phosphatidylcholine, 4% His tag-conjugating lipid, DGS-NTA-(Ni2+) and 36% cholesterol (Avanti Polar Lipids).
Lipid components were dissolved in chloroform, mixed and placed for two hours in a desiccator under vacuum at room temperature to obtain a lipid film. The film was hydrated in filtered (0.22 pm) PBS and liposomes were prepared by extrusion using membrane filters with a pore size of 0.1 pm (Whatman0 Nuclepore0 Track-Etched membranes). The integrity and size of the liposomes was analyzed by negative staining-EM.
For protein coupling, the liposomes were incubated overnight with FA-S protein or S protein in a 3:1 ratio (w/w).
Free FA-S protein was separated from the FA-S-proteoliposomes (S-LVs) by sucrose gradient (5-40%) centrifugation in a 5W55 rotor at 40,000 rpm for 2 h.
The amount of protein conjugated to the liposomes was determined by Bradford assay and SDS-PAGE densitometry analysis comparing S-LV bands with standard S protein concentrations.
Trimer thermostability Thermal denaturation of S protein, native or FA-cross-linked was analyzed by differential scanning fluorimetry coupled to back scattering using a Prometheus NT.48 instrument (Nanotemper Technologies). Protein samples were first extensively dialyzed against PBS pH 7.4, and the protein concentration was adjusted to 0.3 mg/ml. 10 pL of sample were loaded into the capillary and intrinsic fluorescence was measured at a ramp rate of 1 C/min with an excitation power of 30 %. Protein unfolding was monitored by the changes in fluorescence emission at 350 and 330 nm. The thermal unfolding midpoint (Tm) of the proteins was determined using the Prometheus NT software.
Negative stain electron microscopy Protein samples were visualized by negative-stain electron microscopy (EM) using 3-4 pL aliquots containing 0.1-0.2 mg/ml of protein. Samples were applied Date Recue/Date Received 2022-06-15
26 for 10 s onto a mica carbon film and transferred to 400-mesh Cu grids that had been glow discharged at 20 mA for 30 s and then negatively stained with 2%
(wt/vol) Uranyl Acetate (UAc) for 30 s. Data were collected on a FEI Tecnai LaB6-EM operating at 120 kV accelerating voltage at 23k magnification (pixel size of 2.8 A) using a Gatan Onus 1000 CCD Camera. Two-dimensional (2D) class averaging was performed with the software Relion using on average 30-40 micrographs per sample. The 5 best obtained classes were calculated from around 6000 particles each.
Cryo-electron microscopy Data collection. 3.5 pL of sample were applied to 1.2/1.3 C-Flat (Protochips Inc) holey carbon grids and plunged frozen in liquid ethane with a Vitrobot Mark IV (Thermo Fisher Scientific) (6 s blot time, blot force 0). The sample was observed with a Glacios0 electron microscope (Thermo Fischer Scientific) at 200 kV. Images were recorded automatically on a K2 summit direct electron detector (Gatan Inc., USA) in counting mode with SerialEM. Movies were recorded for a total exposure of 4.5 s with 40 frames per movie and a total dose of 40 e-/A2. The magnification was 36,000x (1.15 A/pixel at the camera level).
The defocus of the images was changed between -1.0 and -2.5 pm. Two different datasets have been acquired on the same grid. First, 1040 movies were recorded with stage movement between each hole and then 7518 more movies were recorded with image shifts on a 3x3 hole pattern.
3D reconstruction. The movies were first drift-corrected with MotionCor2. The remaining image processing was performed with RELION 3.1.2 and CTF
estimation with GCTF. An initial set of particles (box size of 200 pixels, sampling of 2.3 A/pixel) was obtained by auto-picking with a Gaussian blob. After 2D
classification, the best looking 2D class averages were used for a second round of auto picking. Following another 2D classification step, the particles belonging to the best looking 2D class averages were used to create an ab-initio starting 3D model which was then used to calculate a first 3D reconstruction with C3 symmetry. The 2D projections from that 3D model were then used to do one last auto picking which resulted in a total of 2,582,857 particles. Following another 2D classification and a 3D classification (Cl symmetry, 5 classes) steps, a 3D
map at 4.6 A resolution was obtained from 240,777 particles. The particles were Date Recue/Date Received 2022-06-15
(wt/vol) Uranyl Acetate (UAc) for 30 s. Data were collected on a FEI Tecnai LaB6-EM operating at 120 kV accelerating voltage at 23k magnification (pixel size of 2.8 A) using a Gatan Onus 1000 CCD Camera. Two-dimensional (2D) class averaging was performed with the software Relion using on average 30-40 micrographs per sample. The 5 best obtained classes were calculated from around 6000 particles each.
Cryo-electron microscopy Data collection. 3.5 pL of sample were applied to 1.2/1.3 C-Flat (Protochips Inc) holey carbon grids and plunged frozen in liquid ethane with a Vitrobot Mark IV (Thermo Fisher Scientific) (6 s blot time, blot force 0). The sample was observed with a Glacios0 electron microscope (Thermo Fischer Scientific) at 200 kV. Images were recorded automatically on a K2 summit direct electron detector (Gatan Inc., USA) in counting mode with SerialEM. Movies were recorded for a total exposure of 4.5 s with 40 frames per movie and a total dose of 40 e-/A2. The magnification was 36,000x (1.15 A/pixel at the camera level).
The defocus of the images was changed between -1.0 and -2.5 pm. Two different datasets have been acquired on the same grid. First, 1040 movies were recorded with stage movement between each hole and then 7518 more movies were recorded with image shifts on a 3x3 hole pattern.
3D reconstruction. The movies were first drift-corrected with MotionCor2. The remaining image processing was performed with RELION 3.1.2 and CTF
estimation with GCTF. An initial set of particles (box size of 200 pixels, sampling of 2.3 A/pixel) was obtained by auto-picking with a Gaussian blob. After 2D
classification, the best looking 2D class averages were used for a second round of auto picking. Following another 2D classification step, the particles belonging to the best looking 2D class averages were used to create an ab-initio starting 3D model which was then used to calculate a first 3D reconstruction with C3 symmetry. The 2D projections from that 3D model were then used to do one last auto picking which resulted in a total of 2,582,857 particles. Following another 2D classification and a 3D classification (Cl symmetry, 5 classes) steps, a 3D
map at 4.6 A resolution was obtained from 240,777 particles. The particles were Date Recue/Date Received 2022-06-15
27 re-extracted (box size of 400 pixels, sampling of 1.15 A/pixel). After another refinement (C3 symmetry) and 3D classification (Cl symmetry, no alignment, 3 classes) steps, a final set of 126,719 particles was identified which resulted in a 3D reconstruction at 3.6 A resolution. Refinement of CTF parameters, particle polishing and a second round of CTF parameter's refinement further improved the resolution to 3.4 A. The resolution was determined by Fourier Shell Correlation (FSC) at 0.143 between two independent 3D maps. The local resolution was calculated with blocres and found to be between 3 and 5 A. The final 3D map was sharpened with DeepEMhancer.
Model refinement. The atomic model of the S protein in the closed conformation (PDB 6VXX) was rigid-body fitted inside the cryo-EM density map in CHIMERA.
The atomic coordinates were then refined with PHENIX. The refined atomic models were visually checked and adjusted (if necessary) in COOT. The final model was validated with MOLPROBITY.
The figures were prepared with CHIMERA and CHIMERAX. The atomic coordinates and the cryo-EM map have been deposited in the Protein Data Bank and in the Electron Microscopy Data Bank under the accession codes 7QIZ and EMD-13776, respectively.
Virus quantification in NHP samples Upper respiratory (nasopharyngeal and tracheal) and rectal specimens were collected with swabs (Viral Transport Medium, CDC, DSR-052-01). Tracheal swabs were performed by insertion of the swab above the tip of the epiglottis into the upper trachea at approximately 1.5 cm of the epiglottis. All specimens were stored between 2 C and 8 C until analysis by RT-qPCR with a plasmid standard concentration range containing an RdRp gene fragment including the RdRp-IP4 RT-PCR target sequence. SARS-CoV-2 E gene subgenomic mRNA (sgRNA) levels were assessed by RT-qPCR using the following primers and probe:
- leader-specific primer sgLeadSARSCoV2-F of sequence:
CGATCTCTTGTAGATCTGTTCTC (SEQ ID No: 10), - E-Sarbeco-R primer of sequence:
ATATTGCAGCAGTACGCACACA (SEQ ID No: 11), - and E-Sarbeco probe of sequence:
HEX-ACACTAGCCATCCTTACTGCGCTTCG-BHQ1 (SEQ ID No: 12), Date Recue/Date Received 2022-06-15
Model refinement. The atomic model of the S protein in the closed conformation (PDB 6VXX) was rigid-body fitted inside the cryo-EM density map in CHIMERA.
The atomic coordinates were then refined with PHENIX. The refined atomic models were visually checked and adjusted (if necessary) in COOT. The final model was validated with MOLPROBITY.
The figures were prepared with CHIMERA and CHIMERAX. The atomic coordinates and the cryo-EM map have been deposited in the Protein Data Bank and in the Electron Microscopy Data Bank under the accession codes 7QIZ and EMD-13776, respectively.
Virus quantification in NHP samples Upper respiratory (nasopharyngeal and tracheal) and rectal specimens were collected with swabs (Viral Transport Medium, CDC, DSR-052-01). Tracheal swabs were performed by insertion of the swab above the tip of the epiglottis into the upper trachea at approximately 1.5 cm of the epiglottis. All specimens were stored between 2 C and 8 C until analysis by RT-qPCR with a plasmid standard concentration range containing an RdRp gene fragment including the RdRp-IP4 RT-PCR target sequence. SARS-CoV-2 E gene subgenomic mRNA (sgRNA) levels were assessed by RT-qPCR using the following primers and probe:
- leader-specific primer sgLeadSARSCoV2-F of sequence:
CGATCTCTTGTAGATCTGTTCTC (SEQ ID No: 10), - E-Sarbeco-R primer of sequence:
ATATTGCAGCAGTACGCACACA (SEQ ID No: 11), - and E-Sarbeco probe of sequence:
HEX-ACACTAGCCATCCTTACTGCGCTTCG-BHQ1 (SEQ ID No: 12), Date Recue/Date Received 2022-06-15
28 wherein HEX represents hexachlorofluorescein and BHQ1 represents the BHQ1 quencher.
The protocol describing this procedure for the detection of SARS-CoV-2 is available on the WHO website (https://www.who.int/docs/default-sou rce/coronavi ruse/whoi n ho useassays. pdf).
Chest CT and image analysis Lung images were acquired using a computed tomography (CT) system (Vereos-Ingenuity, Philips), and analyzed using INTELLISPACE PORTAL 8 software (Philips Healthcare). All images had the same window level of -300 and window width of 1,600. Lesions were defined as ground glass opacity, crazy-paving pattern, consolidation or pleural thickening. Lesions and scoring were assessed in each lung lobe blindly and independently by two persons and the final results were established by consensus. Overall CT scores include the lesion type (scored from 0 to 3) and lesion volume (scored from 0 to 4) summed for each lobe.
ELISA
Serum antibody titers specific for soluble native S glycoprotein, FA-cross-linked trimer (FA-S) and for RBD were determined using an enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well micro titer plates were coated with 1 pg of S, FA-S or RBD proteins at 4 C overnight in PBS and blocked with 3% BSA for 1 h at room temperature after 3 washes with 150 pL PBS Tween0-20 0.05 %. Serum dilutions were added to each well for 2h at 37 C and plates were washed 5 times with PBS Tween0. A horseradish peroxidase (HRP) conjugated goat anti-monkey H+L antibody (Invitrogen) was then added and incubated for 1h before excess Ab was washed out and HRP substrate added.
Absorbance was determined at 450 nm. Antibody titers were expressed as ED50 (effective Dilution 50-values) and were determined as the serum dilution at which IgG binding was reduced by 50%. ED50 were calculated from crude data (0.D) after normalization using GraphPad Prism (version 6) "log(inhibitor) vs normalized response" function. ELISA were performed in duplicates.
Protein coupling to Luminex beads Proteins were covalently coupled to MagPlex0 beads (Luminex Corporation) via a two-step carbodiimide reaction using a ratio of 75 pg S trimer to 12,5 million Date Recue/Date Received 2022-06-15
The protocol describing this procedure for the detection of SARS-CoV-2 is available on the WHO website (https://www.who.int/docs/default-sou rce/coronavi ruse/whoi n ho useassays. pdf).
Chest CT and image analysis Lung images were acquired using a computed tomography (CT) system (Vereos-Ingenuity, Philips), and analyzed using INTELLISPACE PORTAL 8 software (Philips Healthcare). All images had the same window level of -300 and window width of 1,600. Lesions were defined as ground glass opacity, crazy-paving pattern, consolidation or pleural thickening. Lesions and scoring were assessed in each lung lobe blindly and independently by two persons and the final results were established by consensus. Overall CT scores include the lesion type (scored from 0 to 3) and lesion volume (scored from 0 to 4) summed for each lobe.
ELISA
Serum antibody titers specific for soluble native S glycoprotein, FA-cross-linked trimer (FA-S) and for RBD were determined using an enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well micro titer plates were coated with 1 pg of S, FA-S or RBD proteins at 4 C overnight in PBS and blocked with 3% BSA for 1 h at room temperature after 3 washes with 150 pL PBS Tween0-20 0.05 %. Serum dilutions were added to each well for 2h at 37 C and plates were washed 5 times with PBS Tween0. A horseradish peroxidase (HRP) conjugated goat anti-monkey H+L antibody (Invitrogen) was then added and incubated for 1h before excess Ab was washed out and HRP substrate added.
Absorbance was determined at 450 nm. Antibody titers were expressed as ED50 (effective Dilution 50-values) and were determined as the serum dilution at which IgG binding was reduced by 50%. ED50 were calculated from crude data (0.D) after normalization using GraphPad Prism (version 6) "log(inhibitor) vs normalized response" function. ELISA were performed in duplicates.
Protein coupling to Luminex beads Proteins were covalently coupled to MagPlex0 beads (Luminex Corporation) via a two-step carbodiimide reaction using a ratio of 75 pg S trimer to 12,5 million Date Recue/Date Received 2022-06-15
29 beads. MagPlex0 beads were washed with 100 mM mono-basic sodium phosphate pH 6.2 and activated for 30 min on a rotor at RT by addition of Sulfo-N-Hydroxysulfosuccinimide (Thermo Fisher Scientific) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (Thermo Fisher Scientific). The activated beads were washed three times with 50 mM MES pH 5.0 and added to S trimer, which was diluted in 50 mM MES pH 5Ø The coupling reaction was incubated for 3 h on a rotator at room temperature. The beads were subsequently washed with PBS and blocked with PBS containing 2% BSA, 3% FCS and 0.02%
Tween0-20 for 30 min on a rotator at room temperature. Finally, the beads were washed and stored in PBS containing 0.05% sodium azide at 4 C and used within 3 months.
Luminex assay 50 pL of a working bead mixture containing 20 beads per pL was incubated overnight at 4 C with 50 pL of diluted nasopharyngeal fluid. Nasopharyngeal fluids were diluted 1:20 for detection of S-specific IgG and IgA. Plates were sealed and incubated on a plate shaker overnight at 4 C. Plates were washed with TBS containing 0.05% Tween0-20 (TBST) using a hand-held magnetic separator. Beads were resuspended in 50 pL of Goat-anti-monkey IgG-Biotin or Goat-anti monkey IgA-Biotin (Sigma Aldrich) and incubated on a plate shaker at RT for 2 h. Afterwards, the beads were washed with TBST, resuspended in 50 pL of Streptavidin-PE (ThermoFisher Scientific) and incubated on a plate shaker at room temperature for 1 h. Finally, the beads were washed with TBST and resuspended in 70 pL Magpix0 drive fluid (Luminex Corporation). The beads were agitated for a few minutes on a plate shaker at room temperature and then readout was performed on the MAGPIXO (Luminex Corporation). Reproducibility of the results was confirmed by performing replicate runs.
Pseudovirus neutralization assay Pseudovirus was produced by co-transfecting the pCR3 SARS-CoV-2-SA19 expression plasmid (Wuhan Hu-1; GenBank: MN908947.3) with the pHIV-1NL43 AEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268).
The pCR3 SARS-CoV-2-S19 expression plasmid contained the following mutations compared to the wild-type for the variants of concern: deletion (A) of H69, V70 and Y144, N501Y, A570D, D614G, P681H, T716I, 5982A and D11 18H
Date Recue/Date Received 2022-06-15
Tween0-20 for 30 min on a rotator at room temperature. Finally, the beads were washed and stored in PBS containing 0.05% sodium azide at 4 C and used within 3 months.
Luminex assay 50 pL of a working bead mixture containing 20 beads per pL was incubated overnight at 4 C with 50 pL of diluted nasopharyngeal fluid. Nasopharyngeal fluids were diluted 1:20 for detection of S-specific IgG and IgA. Plates were sealed and incubated on a plate shaker overnight at 4 C. Plates were washed with TBS containing 0.05% Tween0-20 (TBST) using a hand-held magnetic separator. Beads were resuspended in 50 pL of Goat-anti-monkey IgG-Biotin or Goat-anti monkey IgA-Biotin (Sigma Aldrich) and incubated on a plate shaker at RT for 2 h. Afterwards, the beads were washed with TBST, resuspended in 50 pL of Streptavidin-PE (ThermoFisher Scientific) and incubated on a plate shaker at room temperature for 1 h. Finally, the beads were washed with TBST and resuspended in 70 pL Magpix0 drive fluid (Luminex Corporation). The beads were agitated for a few minutes on a plate shaker at room temperature and then readout was performed on the MAGPIXO (Luminex Corporation). Reproducibility of the results was confirmed by performing replicate runs.
Pseudovirus neutralization assay Pseudovirus was produced by co-transfecting the pCR3 SARS-CoV-2-SA19 expression plasmid (Wuhan Hu-1; GenBank: MN908947.3) with the pHIV-1NL43 AEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268).
The pCR3 SARS-CoV-2-S19 expression plasmid contained the following mutations compared to the wild-type for the variants of concern: deletion (A) of H69, V70 and Y144, N501Y, A570D, D614G, P681H, T716I, 5982A and D11 18H
Date Recue/Date Received 2022-06-15
30 in B.1.1.7 (Alpha, UK); L18F, D80A, D215G, L242H, R246I, K417N, E484K, N501Y, D614G and A701V in B.1.351 (Beta, SA); L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y and T10271 in P.1 (Gamma, BR).
HEK293T/ACE2 cells were seeded at a density of 20,000 cells/well in a 96-well plate coated with 50 pg/mL poly-L-lysine 1 day prior to the start of the neutralization assay. Heat-inactivated sera (1:100 dilution) were serial diluted in 3-fold steps in cell culture medium (DMEM (Gibco), supplemented with 10%
FBS, penicillin (100 U/mL), streptomycin (100 pg/mL) and GlutaMax0 (Gibco), mixed in a 1:1 ratio with pseudovirus and incubated for 1 h at 37 C. These mixtures were then added to the cells in a 1:1 ratio and incubated for 48 h at 37 C, followed by a PBS wash and lysis buffer added. The luciferase activity in cell lysates was measured using the Nano-Glo0 Luciferase Assay System (Promega) and GloMax system (Turner BioSystems). Relative luminescence units (RLU) were normalized to the positive control wells where cells were infected with pseudovirus in the absence of sera. The neutralization titers (ID50) were determined as the serum dilution at which infectivity was inhibited by 50%, respectively using a non-linear regression curve fit (GraphPad Prism software version 8.3). Notably, this pseudovirus neutralization assay revealed an excellent correlation with authentic virus neutralization on a panel of human convalescent sera.
Antigen specific T cell assays using non-human primate cells To analyze the SARS-CoV-2 protein-specific T cell, 15-mer peptides (n = 157 and n=158) overlapping by 11 amino acids (aa) and covering the SARS-CoV-2 Spike sequence (aa 1 to 1273) were synthesized by JPT Peptide Technologies (Berlin, Germany) and used at a final concentration of 2 pg/mL.
T-cell responses were characterized by measurement of the frequency of PBMC
expressing IL-2 (PerCP5.5, MQ1-17H12, BD), IL-17a (Alexa700, N49-653, BD), IFN-y (V450, B27, BD), TNF-a (BV605, Mab11, BioLegend), IL-13 (BV711, JES10-5A2, BD), CD137 (APC, 4B4, BD) and CD154 (FITC, TRAP1, BD) upon stimulation with the two peptide pools. CD3 (APC-Cy7, 5P34-2, BD), CD4 (BV510, L200, BD) and CD8 (PE-Vio770, BW135/80, Miltenyi Biotec) antibodies was used as lineage markers. One million of PBMC were cultured in complete Date Recue/Date Received 2022-06-15
HEK293T/ACE2 cells were seeded at a density of 20,000 cells/well in a 96-well plate coated with 50 pg/mL poly-L-lysine 1 day prior to the start of the neutralization assay. Heat-inactivated sera (1:100 dilution) were serial diluted in 3-fold steps in cell culture medium (DMEM (Gibco), supplemented with 10%
FBS, penicillin (100 U/mL), streptomycin (100 pg/mL) and GlutaMax0 (Gibco), mixed in a 1:1 ratio with pseudovirus and incubated for 1 h at 37 C. These mixtures were then added to the cells in a 1:1 ratio and incubated for 48 h at 37 C, followed by a PBS wash and lysis buffer added. The luciferase activity in cell lysates was measured using the Nano-Glo0 Luciferase Assay System (Promega) and GloMax system (Turner BioSystems). Relative luminescence units (RLU) were normalized to the positive control wells where cells were infected with pseudovirus in the absence of sera. The neutralization titers (ID50) were determined as the serum dilution at which infectivity was inhibited by 50%, respectively using a non-linear regression curve fit (GraphPad Prism software version 8.3). Notably, this pseudovirus neutralization assay revealed an excellent correlation with authentic virus neutralization on a panel of human convalescent sera.
Antigen specific T cell assays using non-human primate cells To analyze the SARS-CoV-2 protein-specific T cell, 15-mer peptides (n = 157 and n=158) overlapping by 11 amino acids (aa) and covering the SARS-CoV-2 Spike sequence (aa 1 to 1273) were synthesized by JPT Peptide Technologies (Berlin, Germany) and used at a final concentration of 2 pg/mL.
T-cell responses were characterized by measurement of the frequency of PBMC
expressing IL-2 (PerCP5.5, MQ1-17H12, BD), IL-17a (Alexa700, N49-653, BD), IFN-y (V450, B27, BD), TNF-a (BV605, Mab11, BioLegend), IL-13 (BV711, JES10-5A2, BD), CD137 (APC, 4B4, BD) and CD154 (FITC, TRAP1, BD) upon stimulation with the two peptide pools. CD3 (APC-Cy7, 5P34-2, BD), CD4 (BV510, L200, BD) and CD8 (PE-Vio770, BW135/80, Miltenyi Biotec) antibodies was used as lineage markers. One million of PBMC were cultured in complete Date Recue/Date Received 2022-06-15
31 medium (RPMI1640 Glutamax0+, Gibco; supplemented with 10 % FBS), supplemented with co-stimulatory antibodies (FastImmune CD28/CD49d, Becton Dickinson). The cells were stimulated with S sequence overlapping peptide pools at a final concentration of 2 pg/mL. Brefeldin A was added to each well at a final concentration of 10 pg/mL and the plate was incubated at 37 C, 5% CO2 during 18 h. Next, cells were washed, stained with a viability dye (LIVE/DEADO fixable Blue dead cell stain kit, ThermoFisher), and then fixed and permeabilized with the BD Cytofix/Cytoperm0 reagent. Permeabilized cell samples were stored at -80 C before the staining procedure. Antibody staining was performed in a single step following permeabilization. After 30 min of incubation at 4 C, in the dark, cells were washed in BD Perm/Wash buffer then acquired on the LSRII cytometer (Beckton Dickinson). Analyses were performed with the FlowJo0 v.10 software. Data are presented as the sum of each peptide pool and the non-stimulated (NS) condition was multiplied by two.
Statistical analysis Statistical significance between groups was performed using Graphpad Prism (v9.2.0). Differences between unmatched groups were compared using an unpaired Mann¨Whitney U test (significance p<0.05), and differences between matched groups were compared using Wilcoxon signed-rank test (p<0.1).
Statistical analysis of NHP gRNA and sgRNA were carried out using Mann-Whitney unpaired Hest in GraphPad Prism software (v8.3.0).
RESULTS
S-LV formation and characterization The S glycoprotein construct 2P' was expressed in mammalian cells and purified by Ni2+-affinity and size exclusion chromatography (SEC), with yields up to 10 mg/liter using Expi293F cells. This produced native trimers as determined by negative staining electron microscopy and 2-D class averaging of the single particles. Chemical cross-linking with 4% formaldehyde (FA) produced preserved the native structure of the S trimer over longer time periods than native S trimer by increasing the thermostability to a Tm of 65 C. The cryo-electron microscopy structure of FA-cross-linked S (FA-S) at 3.4 A resolution revealed two major sites of cross linking, as shown in (A) in figure 1. RBD residues and K378 cross-linked neighboring RBDs producing S trimers in the closed Date Recue/Date Received 2022-06-15
Statistical analysis Statistical significance between groups was performed using Graphpad Prism (v9.2.0). Differences between unmatched groups were compared using an unpaired Mann¨Whitney U test (significance p<0.05), and differences between matched groups were compared using Wilcoxon signed-rank test (p<0.1).
Statistical analysis of NHP gRNA and sgRNA were carried out using Mann-Whitney unpaired Hest in GraphPad Prism software (v8.3.0).
RESULTS
S-LV formation and characterization The S glycoprotein construct 2P' was expressed in mammalian cells and purified by Ni2+-affinity and size exclusion chromatography (SEC), with yields up to 10 mg/liter using Expi293F cells. This produced native trimers as determined by negative staining electron microscopy and 2-D class averaging of the single particles. Chemical cross-linking with 4% formaldehyde (FA) produced preserved the native structure of the S trimer over longer time periods than native S trimer by increasing the thermostability to a Tm of 65 C. The cryo-electron microscopy structure of FA-cross-linked S (FA-S) at 3.4 A resolution revealed two major sites of cross linking, as shown in (A) in figure 1. RBD residues and K378 cross-linked neighboring RBDs producing S trimers in the closed Date Recue/Date Received 2022-06-15
32 "RBD-down" conformation as shown in (A) and (B) in figure 1. The second site introduced inter S2 subunit bonds by cross-linking R1019 of the central S2 helix and/or S2 K776 with S2 HR1 K947 as shown in (C) in figure 1. FA-S was incubated with liposomes (Phosphatidylcholine 60%, Cholesterol 36%, DGS-NTA 4%), and efficiently captured via its C-terminal His-tag. Free, unbound Fa-S was removed from the S proteoliposomes by sucrose gradient centrifugation and decoration of the liposomes with FA-S (S-LV) was confirmed by negative staining electron microscopy as shown in (D) in figure 1.
FA-S-LVs immunization induced potent neutralizing antibody responses in cynomolqus macaques FA-S-LVs were produced for a small vaccination study of cynomolgus macaques to evaluate immunogenicity and elicitation of neutralizing antibodies. Four cynomolgus macaques were immunized with 50 pg S-LVs adjuvanted with monophospholipid A (MPLA) liposomes by the intramuscular route at weeks 0, 4, 8 and 19, as illustrated in (A) in figure 2. Sera of the immunized macaques were analysed for binding to native S glycoprotein (S), FA cross-linked S
glycoprotein (FA-S) and RBD in two weeks intervals. The results revealed similar S-specific Ab titers for all animals. S ED50 titers increased from about 75 on week 4 to about 10000 on week 6 and to about 20000 on week 12, after the first, second and third immunization, respectively, as shown in (B) in figure 2.
Slight reductions in titers were detected against FA-S, as shown in (C) in figure 2.
Titers against RBD alone reached ID50s of about 100 on week 4, about 4500 on week 6 and slight increases on week 12 for some animals, as shown in (D) in figure 2.
This shows that the first and second immunization induced significant RBD
titers, while the third immunization boosted non-RBD antibodies since the week 12 5-specific titers were more than 4 times higher than the RBD-specific titers in contrast to previous time points at which this ratio was lower. A fourth immunization did not further boost antibody generation and titers at week 22 were lower or comparable to week 12 titers. These results demonstrate that FA-S-LV immunization induced primarily RBD-specific antibodies after the first and second immunization, while the third immunization increased the generation of non-RBD antibodies significantly.
Date Recue/Date Received 2022-06-15
FA-S-LVs immunization induced potent neutralizing antibody responses in cynomolqus macaques FA-S-LVs were produced for a small vaccination study of cynomolgus macaques to evaluate immunogenicity and elicitation of neutralizing antibodies. Four cynomolgus macaques were immunized with 50 pg S-LVs adjuvanted with monophospholipid A (MPLA) liposomes by the intramuscular route at weeks 0, 4, 8 and 19, as illustrated in (A) in figure 2. Sera of the immunized macaques were analysed for binding to native S glycoprotein (S), FA cross-linked S
glycoprotein (FA-S) and RBD in two weeks intervals. The results revealed similar S-specific Ab titers for all animals. S ED50 titers increased from about 75 on week 4 to about 10000 on week 6 and to about 20000 on week 12, after the first, second and third immunization, respectively, as shown in (B) in figure 2.
Slight reductions in titers were detected against FA-S, as shown in (C) in figure 2.
Titers against RBD alone reached ID50s of about 100 on week 4, about 4500 on week 6 and slight increases on week 12 for some animals, as shown in (D) in figure 2.
This shows that the first and second immunization induced significant RBD
titers, while the third immunization boosted non-RBD antibodies since the week 12 5-specific titers were more than 4 times higher than the RBD-specific titers in contrast to previous time points at which this ratio was lower. A fourth immunization did not further boost antibody generation and titers at week 22 were lower or comparable to week 12 titers. These results demonstrate that FA-S-LV immunization induced primarily RBD-specific antibodies after the first and second immunization, while the third immunization increased the generation of non-RBD antibodies significantly.
Date Recue/Date Received 2022-06-15
33 Serum neutralization titers using wild-type pseudovirus were elicited in all four animals. At week 2 after the first immunization, a ID50 titer between 100 and 1000 was observed, which dropped close to baseline at week 4, but was significantly increased at week 6, two weeks after the second immunization demonstrating ID50s between 5000 and about 20000. The ID50s then decreased at week 8 and increased to 20000 to about 40000 at week 11, three weeks after the third immunization. At week 19, neutralization potency decreased but was still high, indicating that three immunizations induced robust neutralization titers. The fourth immunization boosted neutralization titers to the same level as after the third immunization, as shown in (A) in figure 3.
The serum at week 11 was depleted by anti-RBD affinity chromatography, resulting in no detectable RBD antibodies by ELISA. RBD-specific Ab-depleted serum showed 10 to 30% neutralization compared to the complete serum, indicating some level of non-RBD specific neutralization. While RBD-specific Ab neutralization largely dominated in two animals, the fraction of non RBD-specific Ab neutralization activity, as shown in (B) in figure 3, appeared greater in the other two animals, suggesting a participation of these Abs in the high neutralization titers.
FA-S-LV immunization protected cynomoldus macaques from SARS-CoV-2 infection In order to determine the extent of FA-S-LV vaccination induced protection, vaccinated and non-vaccinated animals (n=4) were infected with the primary SARS-CoV-2 isolate (BetaCoV/France/IDF/0372/2020) with a total dose of 1 x 105 plaque forming units (pfu). Infection was induced by combining intranasal (0.25 mL into each nostril) and intratracheal (4.5 mL) routes at week 24, 5 weeks after the last immunization. Viral load in the control animal group peaked in the trachea at 3 days post-exposure (dpe) with a median value of 6.0 logio copies/ml and in the nasopharynx between days 4 and 6 pe with a median copy number of 6.6 logio copies/ml, as shown in (A) in figure 4. Viral loads decreased subsequently and no virus was detected on day 10 dpe in the trachea, while some animals showed viral detection up to day 14 dpe in the nasopharyngeal swabs. In the bronchoalveolar lavage (BAL), three CTRL animal out of four showed detectable viral loads at day 3 pe, and two of them remained detectable Date Recue/Date Received 2022-06-15
The serum at week 11 was depleted by anti-RBD affinity chromatography, resulting in no detectable RBD antibodies by ELISA. RBD-specific Ab-depleted serum showed 10 to 30% neutralization compared to the complete serum, indicating some level of non-RBD specific neutralization. While RBD-specific Ab neutralization largely dominated in two animals, the fraction of non RBD-specific Ab neutralization activity, as shown in (B) in figure 3, appeared greater in the other two animals, suggesting a participation of these Abs in the high neutralization titers.
FA-S-LV immunization protected cynomoldus macaques from SARS-CoV-2 infection In order to determine the extent of FA-S-LV vaccination induced protection, vaccinated and non-vaccinated animals (n=4) were infected with the primary SARS-CoV-2 isolate (BetaCoV/France/IDF/0372/2020) with a total dose of 1 x 105 plaque forming units (pfu). Infection was induced by combining intranasal (0.25 mL into each nostril) and intratracheal (4.5 mL) routes at week 24, 5 weeks after the last immunization. Viral load in the control animal group peaked in the trachea at 3 days post-exposure (dpe) with a median value of 6.0 logio copies/ml and in the nasopharynx between days 4 and 6 pe with a median copy number of 6.6 logio copies/ml, as shown in (A) in figure 4. Viral loads decreased subsequently and no virus was detected on day 10 dpe in the trachea, while some animals showed viral detection up to day 14 dpe in the nasopharyngeal swabs. In the bronchoalveolar lavage (BAL), three CTRL animal out of four showed detectable viral loads at day 3 pe, and two of them remained detectable Date Recue/Date Received 2022-06-15
34 at day 7 dpe with mean value of 5.4 and 3.6 logio copies/mL respectively.
Rectal fluids tested positive in one animal, which also had the highest tracheal and nasopharyngeal viral loads. Viral subgenomic RNA (sgRNA), which is believed to estimate the number of infected and productively infected cells collected with the swabs or during the lavage, showed peak copy numbers between day 3/4 and 6 pe in the tracheal and nasopharyngeal fluids, respectively, as shown in (B) in figure 4. In the BALs, the two animals presenting high genomic viral loads also showed detectable sgRNA at days 3 and 7 pe, with medians of 5.1 and 3.1 logio copies/mL respectively.
In contrast to control animals, neither gRNA nor sgRNA was detected at any point in the vaccinated group. The mean gRNA peaks in the trachea and nasopharynx (6.0 and 6.6 logio copies/mL respectively) of the control group were higher (p = 0.0286) than those of the vaccinated group. The area under the curve was also higher in the trachea of the control group (6.2 logio, p=0.286). In the BAL, the difference was not statistically significant due to the low number of animals. The complete absence of viral RNA in the vaccinated group, both in the upper and lower respiratory tract, strongly suggested that sterilizing immunity was induced by vaccination. ID50 antibody titers against S, FA-S and RBD
decreased slightly from the day of infection (week 24) to 4 weeks post exposure (pe), as shown in (A), (B) and (C) in figure 5, although a small increase in Ab titers is observed at week 1 pe (week 25). Ab titers also correlated with a slight decrease in neutralization from week 24 to 4 weeks pe, although one animal showed a small increase in neutralization on week 25, 1 week pe, as shown in (D) in figure 5. This demonstrated that challenge of vaccinated animals did not significantly boost their immune system. In contrast, the control group started to show clear detection of S, FA-S and RBD-specific IgG on week 2 pe (week 26), which correlated with the detection of neutralization on week 2 pe in most animals. Protection of vaccinated animals further correlated with the presence of significant S and RBD-specific IgG and IgA in nasopharyngeal fluids as shown in (E) in figure 2. This indicated that S-LV vaccination induced mucosal immunity that very likely contributed to the sterilizing effect of vaccination.
During the first 14 dpe, all control animals showed mild pulmonary lesions characterized by nonextended ground-glass opacities (GG0s) detected by chest Date Recue/Date Received 2022-06-15
Rectal fluids tested positive in one animal, which also had the highest tracheal and nasopharyngeal viral loads. Viral subgenomic RNA (sgRNA), which is believed to estimate the number of infected and productively infected cells collected with the swabs or during the lavage, showed peak copy numbers between day 3/4 and 6 pe in the tracheal and nasopharyngeal fluids, respectively, as shown in (B) in figure 4. In the BALs, the two animals presenting high genomic viral loads also showed detectable sgRNA at days 3 and 7 pe, with medians of 5.1 and 3.1 logio copies/mL respectively.
In contrast to control animals, neither gRNA nor sgRNA was detected at any point in the vaccinated group. The mean gRNA peaks in the trachea and nasopharynx (6.0 and 6.6 logio copies/mL respectively) of the control group were higher (p = 0.0286) than those of the vaccinated group. The area under the curve was also higher in the trachea of the control group (6.2 logio, p=0.286). In the BAL, the difference was not statistically significant due to the low number of animals. The complete absence of viral RNA in the vaccinated group, both in the upper and lower respiratory tract, strongly suggested that sterilizing immunity was induced by vaccination. ID50 antibody titers against S, FA-S and RBD
decreased slightly from the day of infection (week 24) to 4 weeks post exposure (pe), as shown in (A), (B) and (C) in figure 5, although a small increase in Ab titers is observed at week 1 pe (week 25). Ab titers also correlated with a slight decrease in neutralization from week 24 to 4 weeks pe, although one animal showed a small increase in neutralization on week 25, 1 week pe, as shown in (D) in figure 5. This demonstrated that challenge of vaccinated animals did not significantly boost their immune system. In contrast, the control group started to show clear detection of S, FA-S and RBD-specific IgG on week 2 pe (week 26), which correlated with the detection of neutralization on week 2 pe in most animals. Protection of vaccinated animals further correlated with the presence of significant S and RBD-specific IgG and IgA in nasopharyngeal fluids as shown in (E) in figure 2. This indicated that S-LV vaccination induced mucosal immunity that very likely contributed to the sterilizing effect of vaccination.
During the first 14 dpe, all control animals showed mild pulmonary lesions characterized by nonextended ground-glass opacities (GG0s) detected by chest Date Recue/Date Received 2022-06-15
35 computed tomography (CT). Vaccinated animals showed no significant impact of challenge on CT scores. The only animal showing a lesion score >10 was in the control group. Whereas all control animals experienced monocytoses between days 2 and 8 pe, probably corresponding to a response to infection, monocyte counts remained stable after challenge for the vaccinated monkeys, in agreement with the absence of detectable anamnestic response in the latter animals.
The levels of CD4 and CD8 specific T cells were measured in both groups of animals. Before exposure, Th1 type CD4+ T-cell responses were observed in all vaccinated macaques following ex vivo stimulation of PBMCs with S-peptide pools, as shown in figure 6. None had detectable anti-S CD8+ T cells. No significant difference was observed at day 14 pe, also in agreement with the absence of an anamnestic response in vaccinated animals. In contrast, the anti-S Th1 CD4+ response increased post exposure for most of the control animals.
These results demonstrate that FA-S-LV vaccination can produce sterilizing immunity indicating that such a vaccination scheme would be efficient to interrupt the chain of SARS-CoV-2 transmission.
FA-S-LVs vaccination generated robust neutralization of SARS-CoV-2 variants Serum neutralization was further tested against variants B.1.1.7 (Alpha, UK), B.1.351 (Beta, SA) and P.1 (Gamma, BR). Comparing the sera of the vaccinated and the non-vaccinated group at weeks 24 and 28 showed high neutralization titers for all three variants with median ID50s ranging from 10.000 to 20.000, comparable to wild-type pseudovirus neutralization. However, since the background of pre-exposure serum neutralization of the non-vaccinated challenge group was relatively high (median ID50s ranging from 400 of 1100), the neutralization with purified IgG from serum samples of the vaccinated group from week 8 (after 2 immunizations), week 12 (3 immunizations) and weeks 24 and 28 (4 immunizations) was repeated. This showed median ID50s of about 4500 for wild type (WT) and Alpha on week 8, as shown in figure 7, comparable to WT serum neutralization (Figure 3, (A)). Lower ID50s were observed against Beta and Gamma at week 8, respectively. Neutralization potency was increased after the third immunization (week 12) with median ID50s of about 5000 (WT), about 8000 (Alpha), about 800 (Beta) and 1000 (Gamma). Neutralization titers Date Recue/Date Received 2022-06-15
The levels of CD4 and CD8 specific T cells were measured in both groups of animals. Before exposure, Th1 type CD4+ T-cell responses were observed in all vaccinated macaques following ex vivo stimulation of PBMCs with S-peptide pools, as shown in figure 6. None had detectable anti-S CD8+ T cells. No significant difference was observed at day 14 pe, also in agreement with the absence of an anamnestic response in vaccinated animals. In contrast, the anti-S Th1 CD4+ response increased post exposure for most of the control animals.
These results demonstrate that FA-S-LV vaccination can produce sterilizing immunity indicating that such a vaccination scheme would be efficient to interrupt the chain of SARS-CoV-2 transmission.
FA-S-LVs vaccination generated robust neutralization of SARS-CoV-2 variants Serum neutralization was further tested against variants B.1.1.7 (Alpha, UK), B.1.351 (Beta, SA) and P.1 (Gamma, BR). Comparing the sera of the vaccinated and the non-vaccinated group at weeks 24 and 28 showed high neutralization titers for all three variants with median ID50s ranging from 10.000 to 20.000, comparable to wild-type pseudovirus neutralization. However, since the background of pre-exposure serum neutralization of the non-vaccinated challenge group was relatively high (median ID50s ranging from 400 of 1100), the neutralization with purified IgG from serum samples of the vaccinated group from week 8 (after 2 immunizations), week 12 (3 immunizations) and weeks 24 and 28 (4 immunizations) was repeated. This showed median ID50s of about 4500 for wild type (WT) and Alpha on week 8, as shown in figure 7, comparable to WT serum neutralization (Figure 3, (A)). Lower ID50s were observed against Beta and Gamma at week 8, respectively. Neutralization potency was increased after the third immunization (week 12) with median ID50s of about 5000 (WT), about 8000 (Alpha), about 800 (Beta) and 1000 (Gamma). Neutralization titers Date Recue/Date Received 2022-06-15
36 did not increase after the fourth immunization at week 24 and started to decrease at week 28, as shown in figure 7. These results demonstrate that three immunizations provided robust protection against the variants.
Date Recue/Date Received 2022-06-15
Date Recue/Date Received 2022-06-15
Claims (18)
1. A recombinant SARS-CoV-2 S glycoprotein ectodomain trimer comprising three recombinant protomers each containing at least the SARS-CoV-2 S
glycoprotein ectodomain, wherein:
- in each protomer, the furin cleavage site, situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1), is inactivated/disrupted;
- the amino acid residue at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ
ID No: 1) of another one of said protomers; and - the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers and/or the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue at position 776 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers.
glycoprotein ectodomain, wherein:
- in each protomer, the furin cleavage site, situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1), is inactivated/disrupted;
- the amino acid residue at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ
ID No: 1) of another one of said protomers; and - the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers and/or the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of one of said protomers is covalently linked to the amino acid residue at position 776 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) of another one of said protomers.
2. The trimer as claimed in claim 1, wherein in each protomer the amino acid residues situated at positions 682 to 685 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) are substituted by an amino acid motif of sequence GSAS (SEQ ID No: 2).
3. The trimer as claimed in claim 1 or 2, wherein each protomer is linked to a C-terminal trimerization domain.
4. The trimer as claimed in any of claims 1 to 3, wherein in each protomer the amino acid residue at position 408 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue, the amino Date Recue/Date Received 2022-06-15 acid residue at position 378 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, and said arginine residue of one of said protomers and said lysine residue of another one of said protomers are linked by a methylene bridge.
5. The trimer as claimed in any of claims 1 to 4, wherein in each protomer the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, the amino acid residue at position 1019 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is an arginine residue, and said lysine residue of one of said protomers and said arginine residue of another one of said protomers are linked by a methylene bridge.
6. The trimer as claimed in any of claims 1 to 5, wherein in each protomer the amino acid residue at position 947 in the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1) is a lysine residue, the amino acid residue at position 776 in the amino acid sequence of the native SARS-CoV-2 S
glycoprotein (SEQ ID No: 1) is a lysine residue and said lysine residues are linked by a methylene bridge.
glycoprotein (SEQ ID No: 1) is a lysine residue and said lysine residues are linked by a methylene bridge.
7. The trimer as claimed in any of claims 1 to 6, wherein each protomer comprises at least two proline substitutions at positions 986 and 987 of the amino acid sequence of the native SARS-CoV-2 S glycoprotein (SEQ ID No: 1).
8. The trimer as claimed in any of claims 1 to 7, wherein each protomer is linked to at least one tag at its C-terminal end.
9. The trimer as claimed in any of claims 1 to 8, wherein each protomer comprises the 1208 first amino acid residues of the SARS-CoV-2 S glycoprotein or a protein having at least 90 % amino acid sequence identity therewith.
10. The trimer as claimed in any of claims 1 to 9, which is a homomeric trimer.
11. A method of producing the trimer as claimed in any of claims 1 to 10, comprising:
- expressing nucleic acid molecule(s) encoding said recombinant protomer(s) in a host cell to produce said trimer, Date Recue/Date Received 2022-06-15 - purifying said trimer, and - treating said trimer with formaldehyde.
- expressing nucleic acid molecule(s) encoding said recombinant protomer(s) in a host cell to produce said trimer, Date Recue/Date Received 2022-06-15 - purifying said trimer, and - treating said trimer with formaldehyde.
12. A proteoliposome comprising a lipid vesicle a surface of which is coated by the trimer as claimed in any of claims 1 to 10.
13. The proteoliposome as claimed in claim 12, wherein said lipid vesicle comprises 60 % by weight of L-a-phosphatidylcholine, 36 % by weight of cholesterol and 4 % by weight of a polyhistidine-tag conjugating lipid.
14. A method of preparing the proteoliposome as claimed in claim 12 or 13, comprising incubating said trimer with said lipid vesicle.
15. A vaccine comprising proteoliposomes as claimed in claim 12 or 13, and optionally a pharmaceutically acceptable carrier and/or an adjuvant.
16. The vaccine as claimed in claim 15, in a unit dose comprising 50 to 100 pg of said proteoliposomes.
17. Use of a vaccine as claimed in claim 15 or 16 for treating or preventing a SARS-CoV-2 infection in a subject.
18. Use as claimed in claim 17, wherein the vaccine is administrated to the subject intramuscularly or intranasally.
Date Recue/Date Received 2022-06-15
Date Recue/Date Received 2022-06-15
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3162727A CA3162727A1 (en) | 2022-06-15 | 2022-06-15 | Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3162727A CA3162727A1 (en) | 2022-06-15 | 2022-06-15 | Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3162727A1 true CA3162727A1 (en) | 2023-12-15 |
Family
ID=89158693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3162727A Pending CA3162727A1 (en) | 2022-06-15 | 2022-06-15 | Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3162727A1 (en) |
-
2022
- 2022-06-15 CA CA3162727A patent/CA3162727A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7193522B2 (en) | RSV F protein mutant | |
WO2022088953A1 (en) | Sars-cov-2 rbd conjugated nanoparticle vaccine | |
US20230285539A1 (en) | Vaccines against sars-cov-2 and other coronaviruses | |
CA2919353C (en) | Conformationally stabilized rsv pre-fusion f proteins | |
BE1023087B1 (en) | ANTIGENS OF CYTOMEGALOVIRUS AND USES THEREOF | |
Shi et al. | Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection | |
AU2019228551A1 (en) | Self-assembling nanostructure vaccines | |
WO2021076010A1 (en) | Pharmaceutical agent for inducing specific immunity against sars-cov-2 | |
CN108912215A (en) | Method and composition for dengue virus epitope | |
US20200171143A1 (en) | Virus-like particles comprising zika antigen | |
US20170290905A1 (en) | Vaccine | |
Del Campo et al. | OVX836 heptameric nucleoprotein vaccine generates lung tissue-resident memory CD8+ T-cells for cross-protection against influenza | |
Sulbaran et al. | Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection | |
US20230174588A1 (en) | A vaccine against sars-cov-2 and preparation thereof | |
WO2022173940A1 (en) | Coronavirus spike protein designs, compositions and methods for their use | |
WO2018065931A1 (en) | Vaccine | |
US20240002446A1 (en) | Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine | |
WO2022089233A1 (en) | Recombinant spike protein, and preparation method therefor and application thereof | |
CA3162727A1 (en) | Proteoliposomes comprising a sars-cov-2 s glycoprotein ectodomain and their use as a vaccine | |
CN115779079A (en) | Charge-regulated antigenic protein capable of enhancing synergistic immune efficacy with adjuvant | |
WO2022229817A1 (en) | Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use | |
JP2023182231A (en) | Sars-cov-2 s glycoprotein ectodomain-containing proteoliposomes and use thereof as vaccines | |
JP2023538667A (en) | Vaccine against SARS-COV-2 infection | |
CN115322247A (en) | Novel charge mutant antigen of coronavirus receptor binding region and application | |
CA2828068A1 (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |